

Efficacy of Traditional Chinese
Medicine Therapy in the
Treatment of Chronic Fatigue
Syndrome: A Network Meta-
Analysis of Randomized Clinical
Trials

SUPPLEMENTARY APPENDIX


目录

1	PRISMA diagram.....	1
2	Characteristics of Included studies	3
3	Risk of bias table of included studies.....	22
4	Analyses of the all trials network.....	26
5	GRADE for the primary outcomes	80

1 PRISMA diagram

1.1 PRISMA diagram showing selection of articles for pairwise

and network meta-analysis



2 Characteristics of Included studies

2.1 Characteristics of Included studies (RCTs)

First author(year)	Diagnosis	Participants			Interventions		Outcome measures
		Number(male/female)	Age(mean \pm SD or range)	Disease duration(mean \pm SD or range)	Experimental group(E)	Control group(C)	
Xiao (2014)	199 4C DC	80 (39/41)	E: 40.2 \pm 8.2 years C: 40.6 \pm 8.5 years	E: 0.5~2y ears C: 0.6~2y ears	Mox: semi-fixed points; mainpoints(bilateral BL13、BL15、BL18、BL20、BL23) and additional points(according to TCM syndrome differentiation); 15min/session, 30 sessions for 5 weeks	WM: <i>Vitamin B1</i> 、 <i>Vitamin B6</i> 、 <i>Oryzanol</i> 、 <i>Paroxetine</i> ; 5 weeks	FS-14 ; SF-36; adverse reaction ; overall response rate
Li (2018)	199 4C DC	60 (24/36)	E: 38.4 \pm 3.1 years C: 38.1 \pm 3.2 years	E: 6.10 \pm 18.30 months C: 6.09 \pm 18.17 months	Mox: fixed points(bilateral ST36) ; 15min/session, 20 sessions for 4 weeks	THM: <i>Liuwei Dihuang pill</i> ; one dose daily for 4 weeks	FS-14;overall response rate;CFS clinical symptom score
Xing (2019)	199 4 CD C	80 (28/52)	E: 32.23 \pm 10.35 years C: 36.98	Not reported	MT: <i>Shenqi Zhencao decoction</i> combined with moxibustion (CV4);moxib	Mox: fixed point(CV4) ; 30min/session,20 sessions for 4 weeks	FASA;overall response rate

			±		ustion		
			11.38		30min/sessio		
			years		n, THM one		
					dose daily;		
					20 sessions		
					for 4 weeks		
Qi	199	60	E: 38	E: 27.7	AT: <i>Chaihu</i>	THM:	FS-14、SAS
(201	4	(36/24)	± 9	± 5.8	<i>Longgu Muli</i>	<i>Chaihu</i>	
7)	CD		years	months	<i>Decoction</i>	<i>Longgu</i>	
	C		C: 37	C: 26.5	combined	<i>Muli</i>	
			± 11	± 4.5	with	<i>Decoction;</i>	
			years	months	acupuncture	one dose	
					(semi-fixed	daily for 5	
					points; main	weeks	
					points		
					(bilateral		
					BL13、BL15、		
					BL18、BL20、		
					BL23) and		
					additional		
					points(accor		
					ding to TCM		
					syndrome		
					differentiatio		
					n); de qi		
					required;		
					acupuncture		
					30min/sessio		
					n, THM one		
					dose daily;		
					36 sessions		
					for 5 weeks		
Hua	199	60	E:	E: 14.13	Acu: fixed	WM:	FAI;FS-
ng	4	(29/31)	39.70	± 3.12	points(GV20	<i>Vitamin</i>	14;SAS;SDS;
(201	CD		±9.86	months	、GV29;	<i>B1</i>	overall
7)	C		years	C:	bilateral	<i>Oryzanol,</i>	response
			C:	13.97 ±	HT7 、KI3 、	<i>once daily</i>	rate
			41.73	3.23	LR3 、SP6 、	<i>for 2</i>	
			±9.33	months	ST36); de qi	<i>months</i>	
			years		required;		
					40min/sessio		
					n, 16		
					sessions for 2		
					months		

Hu (2013)	199 4 CD C	60 (25/35)	E: 37.36 ±8.55 years C: 37.20 ±6.93 years	E: 38.27 ± 8.73 months C: 39.30 ± 7.55 months	AT: acupuncture combined with THM; fixed points(GV20 、 CV4 、 CV6;bilateral BL15、 BL17、 BL18、 BL20、 PC6 、 LI4 、 ST36 、 LR3); de qi required; 30min/sessio n, 12 sessions for 4 weeks; <i>Liuwei Dihuang pill</i> ; three times daily for 4 weeks	THM: <i>Liuwei Dihuang pill</i> ; three times daily for 4 weeks	FAI;WHOQO L- BREF;overall response rate; CFS clinical symptom score
Xiong (2005)	199 4 CD C	87 (25/62)	E: 18~5 0year s C: 18~5 0year s	E: 6~12 months C: 6~12m onths	Acu: fixed points(bilate ral BL13 、 BL15、 BL18、 BL20、 BL23); de qi required; 30min/sessio n, 20 session for 4 weeks	THM: <i>Liuwei Dihuang pill</i> ; twice daily for 4 weeks	Overall response rate;FS- 14;SCL-90; adverse reaction
Xu (2014)	199 4 CD C	95 (51/44)	E: AT 20~5 0 years C: THM WM 20~5 0 years WM	E: 0.5~3 years C: THM 0.5~3 years WM 0.5~3 years	AT: fixed points(GV14 、 BL43、 GV4、 CV6 、 ST36); de qi required; 15min/sessio n, 20 sessions for 4 weeks; <i>Qingshu Yiqi</i>	THM: <i>Qingshu Yiqi decoction</i> ; once daily for 4 weeks WM: <i>oryzanol</i> 、 <i>diazepam</i> ; symptoma tic	Overall response rate

			20~50 years		<i>decoction</i> ; once daily for 4 weeks	treatment	
Hou (2017)	199 (2017)	54 (30/24)	E: 43.04 ± 9.31 years C: 45.62 ± 9.92 years	E: 52.54 ± 15.23 days C: 48.35 ± 16.93 days	Mox: fixed points(GV14 ~GV2); 15min/session, 6 sessions for 3 months	Acu: semi-fixed points(GV2 9、GV20; bilateral KI3、HT7、SP6、LR3) and additional points(according to TCM syndrome differentiation); 30min/session, 48 sessions for 3 months	FS-14; CFS clinical symptom score; overall response rate; adverse reaction
Xu (2019)	199 (2019)	94 (56/38)	E: 41.5 ± 5.3 years C: 42.5 ± 3.6 years	Not reported	Mox: fixed points(GV14 ~GV2); 15min/session, 6 sessions for 3 months	Acu: semi-fixed points; main points(GV2 9; bilateral KI3、HT7、SP6、LR3) and additional points(according to TCM syndrome differentiation); 30min/session, 48 sessions for 3 months	Overall response rate; FS-14; CFS clinical symptom score

			months					
Liu (2018)	199 4 CD C	88 (19/69)	E: AM 37.39 ±8.47 years	E: AM 18.29 ± 5.81 months	AM : Mox fixed points (GV14~GV2); 40min/session, 8 sessions for 4 weeks; Acu fixed points(GV20 、CV4、BL20、 BL18、BL23、 ST36、SP6); de qi required 30min/session, 8 sessions for 4 weeks	Mox: fixed points (GV14~GV 2); 40min/sess ion,8 sessions for 4 weeks Acu: fixed points(GV2 0、CV4、 BL20、 BL18、 BL23、 ST36、 SP6);de qi required; 30min/sess ion, 8 sessions for 4 weeks	Overall response rate;FS- 14;FAI	
Shi (2015)	199 4 CD C	59 (17/42)	E: 39.00 ± 12.54 years	E : 13.00 ± 4.94 months	Mox : fixed points (GV14~GV 2 ; BL11~BL26) ; 30min/session , 12 sessions for 6 weeks	Acu: semi- fixed points; main points(GV2 0、PC6、 CV4、ST36、 KI3、BL20、 BL23、GV4) and additional points(acc ording to TCM syndrome differentiat ion); de qi required; 30min/sess ion, 18 sessions for 6 weeks	FS- 14;SAS;over all response rate; adverse reaction	

Luo Dai Hong	1994	60 (31/29)	E: 43 ± 4 years C: 42 ± 3 years	E: 11.9 ± 4.4 months C: 11.1 ± 3.7 months	Mox: fixed points (GV14~GV2; BL11~BL26); 30min/session, 30 sessions for 2 months	Acu: fixed points(GV20、CV6、CV4; bilateral BL20、BL23、ST36、PC6); de qi required; 30min/session, 30 sessions for 2 months	FS-14; overall response rate; adverse reaction
Zhou (2018)	1994	96 (30/66)	E: 35.2 ± 8.5 years C: 34.7 ± 8.3 years	E: 1.0 ± 0.4 years C: 1.1 ± 0.4 years	AM: fixed points(CV12、CV10、CV6、CV4; bilateral ST24、ST26、SP15、KI13); de qi required; 30min/session, 20 sessions for 6 weeks; Mox fixed points(CV6、CV4); 30min/session, 20 sessions for 6 weeks	Acu: fixed points(CV12、CV10、CV6、CV4; bilateral ST24、ST26、SP15、KI13); de qi required; 30min/session, 20 sessions for 6 weeks	FS-14; overall response rate
Zhu (2012)	1994	60 (25/35)	E: 26.98 ± 9.54 years C: 28.58 ± 12.67 years	E: 18.72 ± 14.00 months C: 20.08 ± 16.11 months	Acu: semi-fixed main points(CV12、CV10、CV6、CV4、ST25、ST26、ST24、CV9) and additional points(according to TCM	THM: Chinses herb decoctions according to syndrome differentiation; 10 days	FSS;HAMA;VAS;HAMD; overall response rate; adverse reaction

syndrome
differentiation);
30min/session,
10 sessions for 3
weeks

Tian (2015)	1994	72 (40/32)	E: 42 ± 9 years C: 42 ± 10 years	Not reported	Mox: fixed points(BL43、CV6、ST36);30min/session,30 sessions for 1 month	Acu: fixed points(BL43、CV6、ST36); de qi required;30min/session,30 sessions for 1 month	FAI;overall response rate; adverse reaction
Jiang (2015)	1994	60 (24/36)	E: 37 ± 9 years C: 39 ± 11 years	Not reported	MT: Mox fixed points(CV12、CV4、CV6、ST36、PC6); 15min/session, 18 sessions for 3 weeks THM <i>Bazhen decoction</i> ; one dose daily for 3 weeks	Acu: fixed points(CV20、CV29、TF4、PC6、LR3、ST36、SP6); de qi required; 30min/session, 18 sessions for 3 weeks	FS-14;overall response rate
Guo (2016)	1994	60 (29/31)	E: 45.48 ± 8.32 years C: 46.31 ± 7.95 years	E: 58.32 ± 10.65 months C: 60.58 ± 11.57 months	MT: Mox fixed points(CV6; bilateral ST36、BL20); 15min/session, 20 sessions for 1 month THM <i>Bazhen decoction</i> ; one dose	THM: <i>Bazhen decoction</i> ; one dose daily for 1 month	Overall response rate;FS-14; adverse reaction

<i>daily for 1 month</i>							
Zhao (2014)	199 4 CD C	60 (19/41)	E: 40.80 ±6.60 years C : 41.07 ±5.78 years	E: 11.57 ± 3.58 months C: 11.13 ± 2.98 months	Mox: fixed points(CV4; bilateral BL20、BL23、 ST36); 15min/sessio n, 20 sessions for 4 weeks	Acu: fixed points(GV2 0、CV4、 BL18、 BL20、 BL23、 ST36、 CV17); de qi required; 30min/sess ion, 20 sessions for 4 weeks	FS- 14;SDS;SAS; overall response rate
Luo Wen (2019)	199 4 CD C	90 (32/58)	E: 37.58 ±6.48 years C: 38.25 ±6.26 years	E: 10.42 ± 3.22 months C: 11.06 ± 3.18 months	AM: Acu fixed points(CV13 、CV12、 CV10、CV4、 CV6 ; bilateral ST25、ST36、 SP6); de qi required; 30min/sessio n, 28 sessions for 4 weeks; Mox fixed point(CV8); 6min/session , 28 sessions for 4 weeks	Acu: fixed points(CV1 3、CV12、 CV10、 CV4、CV6; bilateral ST25、 ST36、SP6); de qi required; 30min/sess ion, 28 sessions for 4 weeks;	FSS;SF- 36;overall response rate
Zhen g (2014)	199 4 CD C	86 (44/42)	E: 43.5 ± 13.2 years C: 42.6 ± 12.9 years	E: 2.85 ± 0.89 years C: 2.82 ± 0.92 years	Mox: fixed points(bilate ral ST36、 GB39); de qi required; 5min/session , 21 sessions for 4 weeks	Acu: semi- fixed points; main points(GV2 0、GV29、 TF4、KI3、 LR3、ST36、 SP6) and	Overall response rate; adverse reaction

additional points(according to TCM syndrome differentiation); de qi required; 30min/sessions, 21 sessions for 4 weeks

Wan g (201 3)	199 4 CD C	80 (25/55)	E: 39 ± 6 years C: 38 ± 8 years	E: 23.6 ± 2.9 months C: 25.1 ± 3.3 months	Mox: fixed points(GV20 、 EX-HN1); 1min/session 、 20 sessions for 3 weeks	WM: Fluoxetine hydrochlor ide; 20mg/d for 3 weeks	Overall response rate; adverse reaction
Sui (201 5)	199 4 CD C	60 (27/33)	E: 44.2± 4.2 years C: 45.3± 5.1 years	E: 9.7± 2.5 months C: 10.1 ± 3.1 months	Mox: fixed points(CV4、 CV6、 GV4; bilateral BL20、 BL15、 PC6 、 ST36); 30min/sessio n, 56 sessions for 2 weeks	THM: <i>Guipi pill</i> ; 10 pills/bid for 2 months	Overall response rate
Hao (201 3)	199 4 CD C	59 (24/35)	E: 35.07 ±7.77 years C: 37.07 ±8.00 years	E: 26.53 ± 14.29 months C: 23.79 ± 14.26 months	AM: Acu semi- fixed points;main points and additional points(accor ding to TCM syndrome differentiat ion); de qi required; 20min/sessio n, 24 sessions for 8 weeks	Acu: semi- fixed points;mai n points(GV2 0 、 GV29; bilateral TF4、 KI3、 LR3 、 SP6) and additional points(acc ording to TCM syndrome differentiat	FS- 14;overall response rate; adverse reaction

						Mox fixed point(CV8); 20min/sessio n, 24 sessions for 8 weeks	ion); de qi required; 30min/sess ion, 24 sessions for 8 weeks	
Li Wei Wei (201 6)	199 4 CD C	60 (34/26)	E: 32~6 8 years C: 30~6 0 years	Not reporte d	Acu: semi- fixed points; main points and additional points(accor ding to TCM syndrome differentiatio n); de qi required; 30min/sessio n, 30 sessions for 1 month;	THM: FS- <i>Buzhong</i> <i>Yiqi</i> <i>decoction</i> combined with <i>Liuwei</i> <i>Dihuang</i> <i>pill</i> ; one dose daliy for 1 month	14;overall response rate;SDS	
Lin (201 0)	199 4 CD C	60 (19/41)	E: 38.27 ± 7.49 years C: 39.77 ± 5.58 years	Not reporte d	AM: fixed points(bilate ral BL13、 BL15、BL18、 BL20、 BL23);de qi required; 30min/sessio n, 15 sessions for 3 weeks	THM: Guipi pill; 6g/tid for 3 weeks	FS- 14;FSS;overa ll response rate; adverse reaction	
Song (201 6)	199 4 CD C	57 (20/37)	E: 35.06 ± 1.35 years C: 35.50 ± 1.40 years	E: 17.56 ± 0.48 months C: 17.30 \pm 0.44 months	AM: fixed points(BL23、 BL18、BL20、 ST36、SP6、 GV20); de qi required; 30min/sessio n, 30 sessions for 1 month	THM: FS- <i>Yougui pill</i> ; 9g/tid for 1 month	14;overall response rate; adverse reaction	
Liu You	199 4	70 (23/47)	E: 40.6 \pm	E: 14.5 ± 6.7	Acu: fixed points(BL13、	AM: fixed points(BL1	Overall response	

Bao (2017)	CD C		8.5 years C: 40.5 ± 8.4 years	months C: 14.4 ± 6.7 months	BL15、BL18、BL20、BL23、ST36、SP9、SP6、CV4、CV6、CV12、CV10); de qi required; 30min/session	3、BL15、BL18、BL20、BL23、ST36、SP9、SP6、CV4、CV6、CV12、CV10); de qi required; 30min/session	rate
Zhong (2014)	199 CD 4 C	60 (21/39)	E: 41 ± 8 years C: 41 ± 8 years	E: 14.32 ± 6.33 months C: 15.42 ± 6.05 months	AM: Acu fixed points(bilateral BL13、BL15、BL18、BL20、BL23、ST36、SP6、SP9; CV12、CV10、CV6、CV4); de qi Mox fixed points; 30min/session, 20 sessions for 3 weeks	Acu: fixed points(bilateral BL13、BL15、BL18、BL20、BL23、ST36、SP6、SP9; CV12、CV10、CV6、CV4); de qi required; 30min/session, 20 sessions for 3 weeks	Overall response rate
Zhou (2013)	199 CD 4 C	99 (46/53)	E: AM 40.83 ± 9.13 years C: AM 43.86 ± 5.93 years THM 41.32 ± 7.02 years	E: AM 13.57 ± 4.51 months C: AM 12.31 ± 1.03 months THM 14.81 ± 2.78 months	AM: semi-fixed points; main points(BL15、BL20、ST36、SP6、GV20) and additional points(according to TCM syndrome differentiation); de qi	Acu: semi-fixed points: main points(BL15、BL20、ST36、SP6、GV20) and additional points(according to TCM syndrome	Overall response rate;FS-14;SAS;WH OQOL-BREF; adverse reaction

					required; 30min/session, 30 sessions for 6 weeks	differentiat ion); de qi required; 30min/sess ion, 30 sessions for 6 weeks THM: <i>Guipi decoction</i> , one dose daliy for 6 weeks	
Liu Chun (201 7)	199 4 CD C	60 (26/34)	E: 37.58 ± 12.36 years C: 42.37 ± 14.45 years	E: 11.24 ± 4.07 months C: 10.78 ± 5.12 months	Mox: semi- fixed points; main points(GV29 、 GV20 、 GV24、GV14、 GB20、BL23、 KI3、EX-HN5) and additional points(accor ding to TCM syndrome differentiatio n);30min/ses sion, 48 sessions for 8 weeks	WH: <i>Oryzanol</i> ; 20mg/tid for 8 weeks	FS- 14;overall response rate;SAS;SD S;PSQI
Zhen g (201 2)	199 4 CD C	77 (31/46)	E: 38.73 ±4.11 years C: 37.08 ±5.32 years	E: 18.41± 5.34 months C: 17.12± 6.03 months	Acu: semi- fixed points;main points and additional points(accor ding to TCM syndrome differentiatio n); de qi required;30 min/session, 20 sessions for 4 weeks	NC: Streitberge r's placebo Acupunctu re*	FS- 14;VAS;DSI

An (201 4) CD C	199 4 CD C	80 (35/45)	E: 36.49 ±4.12 years C: 37.08 ±4.69 years	Not reporte d C: 37.08 ±4.69 years	Acu: semi- fixed points;main points and additional points(accor ding to TCM syndrome differentiatio n); de qi required;30 min/session, 20 sessions for 4 weeks	NC: Streitberge r's placebo Acupunctu re*	FS- 14;VAS;DSI
Sai (201 8) CD C	199 4 CD C	62 (30/32)	E: 38.97 ±6.98 years C: 37.73 ±6.26 years	E: 15.72 ± 5.20 months C: 15.23 ± 5.40 months	Mox: fixed points(BL13 ~BL28);10 min/session, 24 seesions for 8 weeks	Acu: fixed points(BL1 2~BL28); de qi required; 30min/sess ion, 24 sessions for 8 weeks	FS- 14;overall response rate
Zhen g (201 3) CD C	199 4 CD C	59 (19/40)	E: 42 ± 6 years C: 43 ± 6 years	E: 21.72 ± 6.04 months C: 22.48 ± 5.64 months	AM: Acu fixed points(BL20、 BL23 LR13、GB25); de qi required; 30min/sessio n, 20 sessions for 4 weeks; Mox fixed points(GV14 ~GV2); 60min/sessio n, 4 sessions for 4 weeks	Acu: fixed points(BL2 0、 BL23 LR13 、 GB25); de qi required; 30min/sess ion, 20 sessions for 4 weeks	FS- 14;VAS;DSI; overall response rate
Li Ron g Zhen	199 4 CD C	62 (30/32)	E: 30.77 ±6.98 years C: 30.77 ±6.98 years	E: 28.10 ± 9.71 months C: 28.10 ±9.71 months	Acu: semi- fixed points; main points(EX-	NC: Usual care	FAI;FS- 14;SAS;SDS; overall response

(2016)			C: 26.75 ± 28.94 ± 6.26 years	E: 8.30 months	HN1、GV24、GV29; bilateral PC6、SP6); de qi required; 30min/session, 18 sessions for 6 weeks		rate
Yu (2013)	1994	60 (15/45) CD C	E: 30~50 years C: 30~50 years	E: 0.5~20 years C: 0.5~20 years	Acu: fixed points(BL20、BL18; bilateral LI4、ST36、LR3、SP9); de qi required; 30min/session, 15 sessions for 3 weeks	THM: <i>Xiaoyao decoction</i> ; one dose daily for 3 weeks	Overall response rate
Zhang (2007)	1994	50 (29/21) CD C	E: 24~61 years C: 18~57 years	E: 1~6 years C: 0.8~5 years	Acu: semi-fixed points; main points(BL18、BL15、BL20、BL23) and additional points(according to TCM syndrome differentiation); de qi required;30 min/session, 20 sessions for 4 weeks	NC: Streitberger's placebo Acupuncture*	FS-14;overall response rate
Wang (2009)	1994	64 (32/32) CD C	E: 35.8 ± 10.7 years C: 38.8 ± 8.8 years	Not reported	Acu: fixed points(GV20、CV17、CV12、CV4、CV6、LI4、ST36、SP6、LR3、KI3、BL20、BL18、	NC: Needling non-acupuncture points; de qi not required*	FS-14; adverse reaction

					BL23); de qi required; 30min/session, 14 sessions for 6 weeks		
Chen (2010)	1994	53 (23/30)	E:37.47 ± 12.21 years C: 39.85 ± 13.47 years	Not reported	Acu: fixed points(ST36、KI3); de qi required; 30min/session, 6 sessions for 2 weeks	NC: Streitberger's placebo Acupuncture*	WHOQOL-BREF;FS-14;overall response rate; adverse reaction
Xu (2016)	1994	62 (35/27)	E: 20~5 years C: 20~5 years	E: 21.31 ± 2.83 months C: 22.87 ± 2.37 months	Acu: semi-fixed points; main points(BL18、BL20、LR3、SP6、GV20、ST36) and additional points(according to TCM syndrome differentiation); de qi required;30 min/session, 20 sessions for 6 weeks	THM: <i>Xiaoyao decoction</i> ; one dose daily for 3 weeks	FAI;SDS;SF-36;overall response rate
Lu (2014)	1994	133 (60/73)	E: 20~5 years C: AM 19~53 years NC 18~54	E: 1~5 years C: AM 0.8~6 years NC 1.2~5.3 years	Acu: fixed points(GV20、CV17、CV4、CV6; bilateral ST36、LI4、LR3、SP6); de qi required; 30min/session, 20 sessions for 3 weeks	AM: Acu fixed points(GV20、CV17、CV4、CV6; bilateral ST36、LI4、LR3、SP6); de qi required; Mox fixed points(GV2	FS-14;

			years							0、CV4、 CV6、 ST36); 30min/sess ion, 20 sessions for 3 weeks NC: Needling non- acupunctu re points; de qi not required*
Wan g (201 8)	199 4 CD C	48 (15/33)	E: 37.3± 7.5 years C: 36.5± 6.9 years	E: 18.5 ± 6.2 months C: 19.4 ± 7.6 months	AM: fixed points(CV4、 CV6; bilateral ST25、 ST36、 KI3、 LR3); de qi required; Mox fixed point(CV4、 CV6、 CV8); 30min/sessio n; 16 sessions for 2 months	Acu fixed points(CV4、 CV6; bilateral ST25、 ST36、 KI3、 LR3); de qi required; 30min/sess ion; 16 sessions for 2 months	Acu: fixed points(CV4、 CV6; bilateral ST25、 ST36、 KI3、 LR3); de qi required; 30min/sess ion; 16 sessions for 2 months	Acu: fixed points(CV4、 CV6; bilateral ST25、 ST36、 KI3、 LR3); de qi required; 30min/sess ion; 16 sessions for 2 months	Overall response rate;FAI; adverse reaction	
Chen (201 8)	199 4 CD C	60 (20/40)	E: 40.77 ± 11.61 years C: 41.47 ± 12.21 years	E: 18.70 ± 9.22 months C: 17.83 ± 9.01 months	Acu: fixed points(bilate ral BL13、 BL15、 BL18、 BL20、 BL23); de qi required; 20min/sessio n, 8 sessions for 4 weeks	NC: Needling non- acupunctu re points; de qi not required*	FS-14;SCL- 90;overall response rate; adverse reaction			
Ding (201 1)	199 4 CD C	60 (35/25)	E: 18~6 5 years C: C: 0.5~3 years	E: 0.5~3 years C: 0.5~3 years	Acu: fixed points(bilate ral BL13、 BL15、 BL18、 BL20、 BL23); de qi required; 20min/sessio n, 8 sessions for 4 weeks	NC: Needling non- acupunctu re points; de qi not required*	FS- 14;SAS;SDS; overall response rate			

			18~6 5 years	years	de required; 30min/sessio n, 18 sessions for 6 weeks	qi de qi not required*		
Ye (200 9)	199 4 CD C	60 (17/43)	E: 20~5 0 years C: 18~5 0 years	E: 0.6~20 years E: 0.6~20 years	Acu: fixed points(BL20、 BL18、 SP9、 ST36 ; bilateral LI4、 LR3); de qi required; 30min/sessio n, 15 sessions for 3 weeks	THM: <i>Xiaoyao decoction</i> ; one dose daily for 3 weeks	Overall response rate	
Yang (201 9)	199 4 CD C	57 (22/35)	E: 37.42 ±9.21 years C: 35.79 ± 10.03 years	E: 38.13 ± 14.04 months C: 37.29 ± 15.12 months	AT: Acu fixed points(CV12; bilateral BL18、 BL20、 ST36、 SP9、 SP6 、 LR3 、 HT7); de qi required;30 min/session, 20 sessions for 4 weeks THM <i>Xiaoyao pill</i> ; 8 pills/bid for 4 weeks	THM: <i>Xiaoyao pill</i> ; 8 pills/bid for 4 weeks	FS-14;SF- 36;overall response rate; adverse reaction	
Yang (201 7)	199 4 CD C	15 (0/15)	E: 24.75 ±3.77 years C: 23.57 ±3.10 years	Not reporte d	Acu: fixed points(BL18、 BL20、 BL23、 ST36、 GV20、 HT7); de qi required; 30min/sessio n, 16 sessions for 4 weeks	NC: Streitberge r's placebo Acupunctu re*	FS- 14;SPHERE; adverse reaction	
Lian g	199 4	59 (20/39)	E: 31.61	E: 27.39 ± 7.18	AM: fixed	Acu NC: Usual care	FAI;FS- 14;SAS;PSQI	

(2016)	CD C		±7.60 years C: 30.54 ±6.87 years	months C: 28.57 ± 7.45 months	points(CV4、 CV6、CV12; bilateral ST25、ST36、 LI4、SP6); de qi required; 30min/sessio n Mox fixed points(CV4、 CV6); 10min/sessio n 16 sessions for 4 weeks	;overall response rate; adverse reaction
--------	---------	--	---	---	--	---

Guan (2017)	199 4 CD C	66 (21/45)	E: 40.6± 9.2 years C: 41.4± 9.6 years	E: 14.2 ± 6.2 months C: 14.6 ± 5.8 months	AM: fixed points(CV4、 CV6; bilateral BL13、BL15、 BL20、BL23、 CV12、CV10、 GB34、ST36、 SP6); de qi required; 30min/sessio n, 10 sessions for 3 weeks	Acu: fixed points(CV4 、 CV6; bilateral BL13 、 BL15 、 BL20 、 BL23 、 CV12 、 CV10 、 GB34 、 ST36、SP6); de qi required; 30min/sess ion, 10 sessions for 3 weeks	Overall response rate
----------------	---------------------	---------------	--	--	---	--	-----------------------------

Wu (2015)	199 4 CD C	100 (38/62)	E: 40.7± 6.0 years C: 40.5± 5.0 years	E: 5.25 ± 1.34 years C: 5.75 ± 1.50 years	AM: fixed points(bilate ral BL13、 BL15、BL18、 BL20、BL23、 ST36、SP6、 SP9、CV12、 CV10、CV6、 CV4); de qi required; 30min/sessio	Acu: fixed points(bila teral BL13、 BL15 、 BL18 、 BL20 、 BL23 、 ST36、SP6、 SP9、CV12、 CV10 、 CV6、CV4);	Overall response rate; adverse reaction
--------------	---------------------	----------------	--	--	--	--	--

n, 10 de qi
 sessions for 3 required;
 weeks 30min/sess
 ion, 10
 sessions
 for 3 weeks

*The points and treatment course in the NC group were same as in the acupuncture group.
 Acronyms: Acu, acupuncture; Mox, moxibustion; AM, acupuncture combined with moxibustion; AT, acupuncture combined with Chinses herbal medicine; MT, moxibustion combined with Chinses herbal medicine; THM, Traditional chinses herbal medicine; WM, western medicine; NC, no control; CDC, Centres for Disease Control and Prevention; FS-14, Fatigue Scale-14; DSI, Depression Status Inventory; FSS, Fatigue Severity Scale; SAS, Self Rating Anxiety Scale; SF-12, SF-20, SF-36: 12, 20, 36-item short-form health survey; VAS, Visual Analogue Scale; WHOQOL-BREF, WHO Quality of Life Assessment Instrument brief version; SDS, Self-Rating Depression Scale; FAI, fatigue assessment instrument; PSQI, Pittsburgh sleep quality index; SPHERE, Somatic and Psychological health report; SCL-90, SymptomChecklist-90; HAMD, Hamilton Depression Scale; HAMA, Hamilton Anxiety Scale.

2.2 General information of each therapy


	Average age	Average course of disease
Acupuncture + Moxibustion	37.94 years	22.34 months
Acupuncture	38.78 years	21.96 months
Moxibustion	40.22 years	14.14 months
Acupuncture + THM	36.95 years	31.28 months
Moxibustion + THM	40.36 years	58.32 months
Traditional Chinses herbal medicine	38.02 years	23.76 months
Western medicine	39.54 years	17.29 months
No control	35.67 years	26.44onths

2.3 Statistics of acupoint frequency

Acupoint	Frequency
BL 13	14
BL 15	16
BL 18	24
BL 20	30
BL 23	22
ST 36	34
CV 4	23
CV 6	17
SP 6	23

3 Risk of bias table of included studies

3.1 The risk of bias graph



3.2 Risk of bias summary

Study ID	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other bias
1.Ding 2011	Low risk of bias	High risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
2.Yu 2013	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
3.Hou 2017	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	High risk of bias	High risk of bias	Unclear risk of bias
4.Liu 2017	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Unclear risk of bias	Unclear risk of bias
5.Liu	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear

2017	of bias	of bias	of bias	of bias	of bias	of bias	risk of bias
6.Liu 2018	Low risk of bias	Unclear risk of bias	Low risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
7.Lu 2014	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Unclear risk of bias	Unclear risk of bias
8.Ye 2009	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
9.Wu 2015	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
10.Zhou 2013	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
11.Zhou 2018	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
12.Jiang 2015	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
13.An 2014	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	High risk of bias	High risk of bias	Unclear risk of bias
14.Song 2016	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
15.Zhang 2007	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
16.Xu 2014	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	High risk of bias	Unclear risk of bias
17.Xu 2019	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Unclear risk of bias	Unclear risk of bias
18.Xu 2010	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
19.Zhu 2012	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias

20.Li 2016	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
21.Li 2018	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
22.Li 2016	Low risk of bias	Low risk of bias	Unclear risk of bias	Unclear risk of bias	High risk of bias	High risk of bias	Unclear risk of bias
23.Yang 2019	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
24.Yang 2017	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
25.Lin 2010	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
26.Liang 2016	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
27.Wang 2013	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Unclear risk of bias	Unclear risk of bias
28.Xiong 2005	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
29.Wang 2009	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
30.Wang 2018	Low risk of bias	High risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Unclear risk of bias	Unclear risk of bias
31.Tian 2015	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
32.Shi 2015	Low risk of bias	High risk of bias	Low risk of bias	Unclear risk of bias	High risk of bias	High risk of bias	Unclear risk of bias
33.Qi 2017	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
34.Luo 2019	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Unclear risk of bias	Unclear risk of bias

		bias	bias	bias		bias	bias
35.Luo 2019	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
36.Xiao 2014	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
37.Hu 2013	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
38.Guan 2107	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	High risk of bias	Unclear risk of bias
39.Sai 2018	Low risk of bias	High risk of bias	High risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
40.Zhao 2014	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
41.Xing 2019	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
42.Zheng 2014	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Unclear risk of bias	Unclear risk of bias
43.Zheng 2012	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
44.Zheng 2013	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Unclear risk of bias	Unclear risk of bias
45.Hao 2013	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
46.Guo 2016	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
47.Zhong 2014	Low risk of bias	High risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Unclear risk of bias	Unclear risk of bias
48.Chen 2018	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias
49.Chen	Low risk	Unclear	Unclear	Low risk	Low risk	Low risk	Unclear

2010	of bias	risk of bias	risk of bias	of bias	of bias	of bias	risk of bias	of bias
50.Sui 2015	Low risk of bias	Unclear risk of bias	Unclear risk of bias	Unclear risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias	of bias
51.Huang 2017	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Low risk of bias	Unclear risk of bias	of bias


4 Analyses of the all trials network

4.1 Estimation of inconsistency: summary of results


Outcome and Data	Number of studies	Number of inconsistent loops out of total (loop-specific method)	Percentage of the inconsistent loops	Number of inconsistent comparisons out of total (SIDE splitting)	Percentage of the inconsistent comparisons	p-value of the DesignbyTreatment test
Overall response rate	46	0/11	0%	1/15	7%	0.3267
FS-14 total score	31	0/5	0%	0/12	0%	0.5026
FS-14 physical score	13	2/3	67%	2/7	29%	0.0004
FS-14 metal score	13	0/3	0%	2/7	29%	0.1187

4.2 Overall response rate of CFS patients

A.Network map




B. Contribution plot



A- Acupuncture with moxibustion; B- Acupuncture; C- Moxibustion; D- Acupuncture with THM; E- Moxibustion with THM; F- Traditional Chinese herbal medicine (THM); G- Western medicine; H- No control

C. Convergence diagram



Potential scale reduction factors:

	Point est.	Upper C.I.
d.2.1	1	1
d.2.3	1	1
d.2.5	1	1
d.2.6	1	1
d.2.7	1	1
d.2.8	1	1
d.6.4	1	1
sd.d	1	1

1- Acupuncture with moxibustion; 2- Acupuncture; 3- Moxibustion; 4- Acupuncture with THM; 5- Moxibustion with THM; 6- Traditional Chinses herbal medicine(THM)
7- Western medicine; 8- No control

D.Trajectories and density diagram

Results on the Log Odds Ratio scale

Iterations = 10010:60000

Thinning interval = 10

Number of chains = 4

Sample size per chain = 5000

1. Empirical mean and standard deviation for each variable,plus standard error of the mean:

	Mean	SD	NaiveSE	Time-seriesSE
d.2.1	1.1375	0.2641	0.001867	0.002901
d.2.3	1.2402	0.2346	0.001659	0.002350
d.2.5	1.5955	0.4778	0.003378	0.004990
d.2.6	-0.3063	0.2761	0.001952	0.002952
d.2.7	-1.2059	0.3912	0.002766	0.004152
d.2.8	-2.2683	0.3345	0.002366	0.003430
d.6.4	1.1750	0.4729	0.003344	0.005340
sd.d	0.4424	0.1952	0.001380	0.005340


2. Quantiles for each variable:


	2.5%	25%	50%	75%	97.5%
d.2.1	0.62007	0.9627	1.1340	1.3085	1.6642
d.2.3	0.78366	1.0830	1.2393	1.3939	1.7094
d.2.5	0.64705	1.2817	1.5991	1.9104	2.5382
d.2.6	-0.86249	-0.4857	-0.3022	-0.1216	0.2227
d.2.7	-1.98612	-1.4614	-1.2038	-0.9470	-0.4376
d.2.8	-2.94538	-2.4843	-2.2649	-2.0475	-1.6148
d.6.4	0.26413	0.8598	1.1608	1.4841	2.1239
sd.d	0.05566	0.3113	0.4492	0.5744	0.8241

3. Model fit (residual deviance):

Dbar: 95.39520 pD: 66.08622 DIC: 161.48142


94 ata points, ratio 1.015, I²= 3%





E.Forest plot

Compared with No Control group



F.League table

Acupuncture with moxibustion					
3.11 (1.86, 5.28)	Acupuncture				
0.9 (0.46, 1.77)	0.29 (0.18, 0.46)	Moxibustion			
1.31 (0.42, 3.96)	0.42 (0.15, 1.16)	1.46 (0.48, 4.63)	Acupuncture		

4.11)	1.18)	4.31)	with THM					
0.63 (0.22, 1.88)	0.2 (0.08, 0.52)	0.7 (0.27, 1.83)	0.48 (0.13, 1.81)	Moxibustion with THM				
4.2 (2.15, 8.68)	1.35 (0.8, 2.37)	4.68 (2.5, 9.05)	3.19 (1.3, 8.36)	6.68 (2.64, 17.21)		Traditional Chinese herbal medicine		
10.38 (4.25, 26.26)	3.33 (1.55, 7.29)	11.47 (5.48, 24.89)	7.91 (2.65, 25.2)	16.58 (5.3, 50.45)		2.47 (1.09, 5.51)	Western medicine	
29.89 (13.09, 71.88)	9.63 (5.03, 19.02)	33.19 (15.17, 75.48)	22.76 (6.71, 79.94)	47.67 (14.93, 147.62)		7.12 (3.02, 16.66)	2.89 (1.03, 7.91)	No control

G. Inconsistency and Heterogeneity

a. Loops of Statistical Inconsistency:

Loop	IF	self	z_value	p_value	CI_95	Loop_Heterog_tau ²
Acu-Mox-MT	1.626	1.033	1.575	0.115	(0.00,3.65)	0.000
Mox-MT-THM	1.171	0.993	1.179	0.238	(0.00,3.12)	0.000
AM-Acu-Mox	1.097	1.056	1.039	0.299	(0.00,3.19)	0.123
Acu-THM-WM	1.015	0.923	1.100	0.271	(0.00,2.82)	0.066
Acu-Mox-THM	0.969	0.767	1.262	0.207	(0.00,2.47)	0.000
Acu-MT-THM	0.513	1.069	0.480	0.631	(0.00,2.61)	0.000
AT-THM-WM	0.495	0.947	0.523	0.601	(0.00,2.35)	0.000
Acu-Mox-WM	0.203	0.741	0.274	0.784	(0.00,1.66)	0.000
Mox-THM-WM	0.182	0.961	0.189	0.850	(0.00,2.07)	0.000
AM-Acu-THM	0.103	0.932	0.111	0.912	(0.00,1.93)	0.287
AM-Mox-THM	0.047	1.324	0.035	0.972	(0.00,2.64)	0.000

b. Side-splitting

Side	Direct		Indirect		Difference		P> z	tau
	Coef.	Std. Err.	Coef.	Std. Err.	Coef.	Std. Err.		
A B	-1.021869	.2556342	-1.655396	.6791747	.6335276	.7194262	0.379	.2592191
A C	-.8185231	.9314647	.1314689	.3259562	-.9499919	.984253	0.334	.2642273
A F	-1.51364	.7129481	-1.251295	.3646051	-.2623453	.8001277	0.743	.2784302
B C	1.322742	.2254018	.4418885	.4133724	.8808536	.4704145	0.061	.1865741
B E	1.029619	.9190925	1.671367	.4468437	-.6417478	1.021959	0.530	.2627105
B F	-.5250864	.3049666	.3042393	.3741198	-.8293257	.4782195	0.083	.1964546
B G	-.7841189	.6390239	-1.282205	.3985133	.4980865	.7531032	0.508	.288318
B H*	-2.092675	.2931997	2.445298	.5337928	-4.537973	.5337929	0.993	.2637588
C E	1.336846	.4935786	-.4138533	.5124342	1.750699	.7114834	0.014	5.20e-07
C F	-.8602012	.7383239	-1.421878	.314402	.5616767	.8024779	0.484	.2936087

C G	-2.322688	.460161	-2.214042	.4892641	-.1086459	.6706003	0.871	.2978023
D F	-1.059243	.4231174	-1.733843	1.427139	.6745994	1.467598	0.646	.2973091
D G	-2.069122	.6728811	-2.002707	.7057275	-.0664147	.9704452	0.945	.2986808
E F	-1.026387	.5379574	-2.466222	.5095211	1.439835	.7409602	0.052	.1034935
F G	-1.259592	.6100866	-.7585859	.444602	-.5010062	.7571358	0.508	.2920758


* All the evidence about these contrasts comes from the trials which directly compare them.

c.Design-by-treatment test

chi2(9) = 10.30


Prob > chi2 = 0.3267

H.Comparison-adjusted funnel plot




I.SUCRA diagram

a.Ranking probability diagram



b. Cumulative probability ranking diagram



AM-Acupuncture with moxibustion; A-Acupuncture; M-Moxibustion; AT-Acupuncture with THM; MT-Moxibustion with THM; T-Traditional Chinses herbal medicine; W-Western medicine; NC-No control.

J. Subgroup analysis

a. age

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	-0.1776	0.5057	0.009056	-1.16	-0.1808	0.8243
SUCRA[1]	0.2049	0.1418	0.002662	0	0.1429	0.4286
SUCRA[2]	0.5863	0.05562	5.20E-04	0.4286	0.5714	0.7143
SUCRA[3]	0.2367	0.1146	0.001594	0	0.2857	0.4286

SUCRA[4]	0.3519	0.133	0.001572	0	0.4286	0.5714
SUCRA[5]	0.06816	0.1137	0.001316	0	0	0.4286
SUCRA[6]	0.6959	0.05103	4.93E-04	0.5714	0.7143	0.7143
SUCRA[7]	0.8575	0.01952	1.24E-04	0.8571	0.8571	0.8571
SUCRA[8]	0.9985	0.0147	7.30E-05	1	1	1
SUCRAz[1]	0.1515	0.1305	9.75E-04	0	0.1429	0.4286
SUCRAz[2]	0.5864	0.05553	5.19E-04	0.4286	0.5714	0.7143
SUCRAz[3]	0.2625	0.1067	9.08E-04	0	0.2857	0.4286
SUCRAz[4]	0.3645	0.1262	0.001353	0	0.4286	0.5714
SUCRAz[5]	0.08316	0.1198	0.00117	0	0	0.4286
SUCRAz[6]	0.696	0.05098	4.93E-04	0.5714	0.7143	0.7143
SUCRAz[7]	0.8575	0.0195	1.24E-04	0.8571	0.8571	0.8571
SUCRAz[8]	0.9985	0.01471	7.31E-05	1	1	1
or[1,2]	0.2944	0.1191	0.002492	0.1224	0.275	0.5726
or[1,3]	1.025	0.4621	0.009107	0.3994	0.9336	2.153
or[1,4]	0.7837	0.5091	0.008041	0.2096	0.6614	2.067
or[1,5]	1.714	1.013	0.01678	0.4671	1.487	4.281
or[1,6]	0.2267	0.1093	0.00192	0.08617	0.2102	0.4606
or[1,7]	0.09516	0.05516	9.16E-04	0.03008	0.08486	0.2215
or[1,8]	0.03226	0.05057	3.44E-04	0.01038	0.02878	0.07384
or[2,3]	3.506	0.7393	0.007745	2.299	3.424	5.182
or[2,4]	2.714	1.436	0.01639	0.975	2.407	6.188
or[2,5]	5.918	2.705	0.03387	2.266	5.372	12.64
or[2,6]	0.7849	0.2038	0.002312	0.4647	0.7619	1.23
or[2,7]	0.3257	0.1161	0.001323	0.1541	0.3077	0.6003
or[2,8]	0.1094	0.05706	4.10E-04	0.05647	0.105	0.1879
or[3,4]	0.7965	0.4307	0.00496	0.2719	0.7038	1.835
or[3,5]	1.717	0.7624	0.009286	0.664	1.571	3.598
or[3,6]	0.2325	0.7771	0.001634	0.1242	0.2218	0.3862
or[3,7]	0.09483	0.09208	4.08E-04	0.04505	0.09029	0.1704
or[3,8]	0.0337	0.6257	0.001192	0.01443	0.03067	0.06175
or[4,5]	2.666	1.759	0.02209	0.6728	2.236	7.251
or[4,6]	0.3438	0.4602	0.00174	0.1353	0.3165	0.7023
or[4,7]	0.1436	0.09081	8.02E-04	0.0468	0.1272	0.3333
or[4,8]	0.0511	0.3544	7.88E-04	0.01422	0.04297	0.1282
or[5,6]	0.1693	7.413	0.01357	0.05921	0.1415	0.3336
or[5,7]	0.06671	0.8261	0.00156	0.02048	0.05693	0.1563
or[5,8]	0.03332	5.986	0.01095	0.006811	0.01936	0.05605
or[6,7]	0.4304	0.1624	0.001651	0.1967	0.404	0.8221
or[6,8]	0.1479	0.06014	6.59E-04	0.0631	0.1378	0.2954
or[7,8]	0.3778	0.1882	0.001944	0.138	0.3398	0.8432
orz[1,1,2]	0.2401	0.07909	3.94E-04	0.1206	0.2296	0.4195
orz[1,1,3]	0.842	0.3329	0.002369	0.3692	0.785	1.642
orz[1,1,4]	0.6521	0.4486	0.004235	0.1808	0.5516	1.702

orz[1,1,5]	1.422	0.8246	0.008581	0.4161	1.236	3.511
orz[1,1,6]	0.1886	0.08641	6.70E-04	0.07734	0.1746	0.3796
orz[1,1,7]	0.07828	0.04163	3.51E-04	0.0275	0.07038	0.1747
orz[1,1,8]	0.0264	0.04752	1.47E-04	0.009776	0.02394	0.05612
orz[1,2,3]	3.506	0.7393	0.007745	2.299	3.424	5.182
orz[1,2,4]	2.714	1.436	0.01639	0.975	2.407	6.188
orz[1,2,5]	5.918	2.705	0.03387	2.266	5.372	12.64
orz[1,2,6]	0.7849	0.2038	0.002312	0.4647	0.7619	1.23
orz[1,2,7]	0.3257	0.1161	0.001323	0.1541	0.3077	0.6003
orz[1,2,8]	0.1094	0.05706	4.10E-04	0.05647	0.105	0.1879
orz[1,3,4]	0.7965	0.4307	0.00496	0.2719	0.7038	1.835
orz[1,3,5]	1.717	0.7624	0.009286	0.664	1.571	3.598
orz[1,3,6]	0.2325	0.7771	0.001634	0.1242	0.2218	0.3862
orz[1,3,7]	0.09483	0.09208	4.08E-04	0.04505	0.09029	0.1704
orz[1,3,8]	0.0337	0.6257	0.001192	0.01443	0.03067	0.06175
orz[1,4,5]	2.666	1.759	0.02209	0.6728	2.236	7.251
orz[1,4,6]	0.3438	0.4602	0.00174	0.1353	0.3165	0.7023
orz[1,4,7]	0.1436	0.09081	8.02E-04	0.0468	0.1272	0.3333
orz[1,4,8]	0.0511	0.3544	7.88E-04	0.01422	0.04297	0.1282
orz[1,5,6]	0.1693	7.413	0.01357	0.05921	0.1415	0.3336
orz[1,5,7]	0.06671	0.8261	0.00156	0.02048	0.05693	0.1563
orz[1,5,8]	0.03332	5.986	0.01095	0.006811	0.01936	0.05605
orz[1,6,7]	0.4304	0.1624	0.001651	0.1967	0.404	0.8221
orz[1,6,8]	0.1479	0.06014	6.59E-04	0.0631	0.1378	0.2954
orz[1,7,8]	0.3778	0.1882	0.001944	0.138	0.3398	0.8432
sd	0.2676	0.1682	0.003084	0.01381	0.2523	0.6262
totresdev	91.72	13.08	0.08468	69.53	91.33	116.2

or: Average age ≤ 40 years orz: Average age > 40 years

b. course of disease

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	-0.00362	0.5349	0.006154	-1.067	-0.00158	1.036
SUCRA[1]	0.1721	0.13	0.002063	0	0.1429	0.4286
SUCRA[2]	0.589	0.05691	5.27E-04	0.4286	0.5714	0.7143
SUCRA[3]	0.2549	0.1124	0.001385	0	0.2857	0.4286
SUCRA[4]	0.3591	0.1295	0.001412	0	0.4286	0.5714
SUCRA[5]	0.07504	0.1198	0.00133	0	0	0.4286
SUCRA[6]	0.6937	0.05301	4.96E-04	0.5714	0.7143	0.7143
SUCRA[7]	0.8575	0.01882	7.82E-05	0.8571	0.8571	0.8571
SUCRA[8]	0.9987	0.01413	6.64E-05	1	1	1
SUCRAz[1]	0.1806	0.1488	9.21E-04	0	0.1429	0.4286
SUCRAz[2]	0.5889	0.05708	5.28E-04	0.4286	0.5714	0.7143
SUCRAz[3]	0.2482	0.1111	9.55E-04	0	0.2857	0.4286
SUCRAz[4]	0.3526	0.1302	0.001311	0	0.4286	0.5714

SUCRAz[5]	0.07996	0.1171	0.001074	0	0	0.4286
SUCRAz[6]	0.6936	0.05328	4.97E-04	0.5714	0.7143	0.7143
SUCRAz[7]	0.8575	0.01882	7.83E-05	0.8571	0.8571	0.8571
SUCRAz[8]	0.9987	0.01411	6.63E-05	1	1	1
or[1,2]	0.2551	0.07716	0.001388	0.1337	0.2462	0.4274
or[1,3]	0.9	0.3228	0.00546	0.4274	0.8479	1.664
or[1,4]	0.7021	0.4068	0.005535	0.2087	0.6135	1.726
or[1,5]	1.506	0.841	0.01146	0.4818	1.342	3.549
or[1,6]	0.2024	0.07818	0.001217	0.09252	0.1922	0.3736
or[1,7]	0.08269	0.03805	5.50E-04	0.03166	0.07561	0.1741
or[1,8]	0.02771	0.03973	2.35E-04	0.01103	0.02529	0.05727
or[2,3]	3.542	0.7373	0.007898	2.342	3.457	5.23
or[2,4]	2.785	1.42	0.01574	0.9975	2.49	6.319
or[2,5]	5.944	2.683	0.02988	2.303	5.435	12.62
or[2,6]	0.8018	0.2044	0.002285	0.4792	0.7804	1.255
or[2,7]	0.3267	0.1155	0.001217	0.1564	0.3096	0.5989
or[2,8]	0.1083	0.0534	4.17E-04	0.05555	0.1034	0.1861
or[3,4]	0.8093	0.4249	0.004693	0.2798	0.721	1.875
or[3,5]	1.707	0.7532	0.008248	0.6706	1.574	3.56
or[3,6]	0.235	0.7855	0.001595	0.1262	0.2254	0.3898
or[3,7]	0.09414	0.09218	3.84E-04	0.04508	0.08943	0.1685
or[3,8]	0.03297	0.6073	0.001131	0.01412	0.02985	0.06033
or[4,5]	2.598	1.851	0.01877	0.6587	2.173	6.966
or[4,6]	0.3419	0.443	0.001818	0.1334	0.3139	0.7061
or[4,7]	0.1405	0.08946	8.32E-04	0.04493	0.1241	0.3284
or[4,8]	0.04946	0.3369	8.83E-04	0.01361	0.04157	0.1242
or[5,6]	0.1714	7.345	0.01343	0.06112	0.1439	0.343
or[5,7]	0.0665	0.8118	0.001532	0.02034	0.05687	0.1579
or[5,8]	0.03237	5.695	0.01041	0.006755	0.01906	0.05464
or[6,7]	0.4233	0.1614	0.001687	0.192	0.3964	0.8067
or[6,8]	0.1434	0.05896	6.84E-04	0.06083	0.1326	0.2839
or[7,8]	0.3735	0.1866	0.002132	0.1344	0.3349	0.8373
orz[1,1,2]	0.2687	0.1282	5.79E-04	0.09932	0.2452	0.5732
orz[1,1,3]	0.9515	0.4948	0.003003	0.3176	0.848	2.183
orz[1,1,4]	0.7481	0.5489	0.004547	0.1684	0.6085	2.152
orz[1,1,5]	1.594	1.1	0.008701	0.3834	1.327	4.37
orz[1,1,6]	0.2156	0.1232	7.94E-04	0.06807	0.1908	0.5053
orz[1,1,7]	0.08781	0.05686	3.86E-04	0.02435	0.07543	0.2229
orz[1,1,8]	0.0293	0.06699	1.95E-04	0.008461	0.02535	0.07188
orz[1,2,3]	3.542	0.7373	0.007898	2.342	3.457	5.23
orz[1,2,4]	2.785	1.42	0.01574	0.9975	2.49	6.319
orz[1,2,5]	5.944	2.683	0.02988	2.303	5.435	12.62
orz[1,2,6]	0.8018	0.2044	0.002285	0.4792	0.7804	1.255
orz[1,2,7]	0.3267	0.1155	0.001217	0.1564	0.3096	0.5989

orz[1,2,8]	0.1083	0.0534	4.17E-04	0.05555	0.1034	0.1861
orz[1,3,4]	0.8093	0.4249	0.004693	0.2798	0.721	1.875
orz[1,3,5]	1.707	0.7532	0.008248	0.6706	1.574	3.56
orz[1,3,6]	0.235	0.7855	0.001595	0.1262	0.2254	0.3898
orz[1,3,7]	0.09414	0.09218	3.84E-04	0.04508	0.08943	0.1685
orz[1,3,8]	0.03297	0.6073	0.001131	0.01412	0.02985	0.06033
orz[1,4,5]	2.598	1.851	0.01877	0.6587	2.173	6.966
orz[1,4,6]	0.3419	0.443	0.001818	0.1334	0.3139	0.7061
orz[1,4,7]	0.1405	0.08946	8.32E-04	0.04493	0.1241	0.3284
orz[1,4,8]	0.04946	0.3369	8.83E-04	0.01361	0.04157	0.1242
orz[1,5,6]	0.1714	7.345	0.01343	0.06112	0.1439	0.343
orz[1,5,7]	0.0665	0.8118	0.001532	0.02034	0.05687	0.1579
orz[1,5,8]	0.03237	5.695	0.01041	0.006755	0.01906	0.05464
orz[1,6,7]	0.4233	0.1614	0.001687	0.192	0.3964	0.8067
orz[1,6,8]	0.1434	0.05896	6.84E-04	0.06083	0.1326	0.2839
orz[1,7,8]	0.3735	0.1866	0.002132	0.1344	0.3349	0.8373
sd	0.2687	0.171	0.003137	0.01302	0.2532	0.6349
totresdev	91.78	12.7	0.08098	69.47	91.41	116.1

or: Average course of disease ≤ 1 year orz: Average course of disease > 1 year

c. Duration of treatment

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B		-3.47	11.14	0.3615	-17.92	-6.031
SUCRA[1]	0.6208	0.4668	0.01511	0	0	1
SUCRA[2]	0.4956	0.1027	0.002473	0.2857	0.2857	0.4286
SUCRA[3]	0.1115	0.1117	0.002515	0	0	0.1429
SUCRA[4]	0.2285	0.127	0.002645	0	0	0.2857
SUCRA[5]	0.2557	0.1553	0.003063	0	0	0.2857
SUCRA[6]	0.5975	0.09265	0.002378	0.4286	0.4286	0.5714
SUCRA[7]	0.7882	0.08417	0.002303	0.7143	0.7143	0.7143
SUCRA[8]	0.9021	0.08482	0.002351	0.7143	0.7143	0.8571
SUCRAz[1]	0.1187	0.1258	0.001347	0	0	0.1429
SUCRAz[2]	0.5838	0.07525	0.00103	0.4286	0.4286	0.5714
SUCRAz[3]	0.1448	0.1228	0.001664	0	0	0.1429
SUCRAz[4]	0.2935	0.142	0.002071	0	0	0.2857
SUCRAz[5]	0.3177	0.176	0.00266	0	0	0.4286
SUCRAz[6]	0.6852	0.0609	7.96E-04	0.5714	0.5714	0.7143
SUCRAz[7]	0.8722	0.04683	5.48E-04	0.8571	0.8571	0.8571
SUCRAz[8]	0.984	0.04531	5.43E-04	0.8571	0.8571	1
or[1,2]	3.65E+06	3.22E+07	1.01E+06	1.45E-08	1.45E-08	101.3
or[1,3]	1.39E+07	1.27E+08	3.93E+06	5.22E-08	5.22E-08	374.4
or[1,4]	1.08E+07	1.16E+08	3.53E+06	3.17E-08	3.17E-08	320.8
or[1,5]	1.01E+07	1.01E+08	2.82E+06	2.64E-08	2.64E-08	352.5
or[1,6]	3.06E+06	2.88E+07	901800	1.08E-08	1.08E-08	99.22

or[1,7]	1.17E+06	1.02E+07	315700	3.97E-09	36.9
or[1,8]	6.38E+05	5.36E+06	1.64E+05	2.33E-09	21.41
or[2,3]	3.842	0.8908	0.01332	2.424	3.725
or[2,4]	2.852	1.87	0.02274	1.075	2.555
or[2,5]	2.873	18.98	0.04744	0.7207	2.294
or[2,6]	0.8218	0.2169	0.003509	0.4791	0.7962
or[2,7]	0.3382	0.1126	0.001582	0.1686	0.3222
or[2,8]	0.1939	0.3103	0.001117	0.09551	0.1842
or[3,4]	0.7717	0.7792	0.006783	0.2701	0.6789
or[3,5]	0.7871	10.17	0.02064	0.1832	0.614
or[3,6]	0.2228	0.1079	0.001146	0.1141	0.2121
or[3,7]	0.09028	0.0477	4.23E-04	0.04461	0.08646
or[3,8]	0.05507	1.149	0.002129	0.02221	0.04899
or[4,5]	1.165	6.767	0.01777	0.2391	0.9069
or[4,6]	0.3389	1.425	0.003339	0.1395	0.3123
or[4,7]	0.1405	0.2899	0.001165	0.0481	0.1266
or[4,8]	0.1007	9.213	0.01685	0.02352	0.07172
or[5,6]	0.3996	0.471	0.003481	0.1085	0.3488
or[5,7]	0.1717	0.2158	0.001845	0.03627	0.1395
or[5,8]	0.1114	5.761	0.01056	0.01921	0.07909
or[6,7]	0.4285	0.1541	0.002083	0.2062	0.4039
or[6,8]	0.2519	0.4052	0.001816	0.1016	0.2311
or[7,8]	0.6541	9.663	0.01954	0.2304	0.5696
orz[1,1,2]	0.2598	0.06602	2.96E-04	0.1563	0.2531
orz[1,1,3]	0.9968	0.4116	0.003638	0.5024	0.943
orz[1,1,4]	0.7397	1.029	0.006403	0.2423	0.6467
orz[1,1,5]	0.7497	8.081	0.01742	0.1664	0.5791
orz[1,1,6]	0.2128	0.1033	9.11E-04	0.1021	0.2012
orz[1,1,7]	0.08767	0.04142	4.15E-04	0.03674	0.0812
orz[1,1,8]	0.05366	1.789	0.003364	0.02068	0.04639
orz[1,2,3]	3.842	0.8908	0.01332	2.424	3.725
orz[1,2,4]	2.852	1.87	0.02274	1.075	2.555
orz[1,2,5]	2.873	18.98	0.04744	0.7207	2.294
orz[1,2,6]	0.8218	0.2169	0.003509	0.4791	0.7962
orz[1,2,7]	0.3382	0.1126	0.001582	0.1686	0.3222
orz[1,2,8]	0.1939	0.3103	0.001117	0.09551	0.1842
orz[1,3,4]	0.7717	0.7792	0.006783	0.2701	0.6789
orz[1,3,5]	0.7871	10.17	0.02064	0.1832	0.614
orz[1,3,6]	0.2228	0.1079	0.001146	0.1141	0.2121
orz[1,3,7]	0.09028	0.0477	4.23E-04	0.04461	0.08646
orz[1,3,8]	0.05507	1.149	0.002129	0.02221	0.04899
orz[1,4,5]	1.165	6.767	0.01777	0.2391	0.9069
orz[1,4,6]	0.3389	1.425	0.003339	0.1395	0.3123
orz[1,4,7]	0.1405	0.2899	0.001165	0.0481	0.1266

orz[1,4,8]	0.1007	9.213	0.01685	0.02352	0.07172
orz[1,5,6]	0.3996	0.471	0.003481	0.1085	0.3488
orz[1,5,7]	0.1717	0.2158	0.001845	0.03627	0.1395
orz[1,5,8]	0.1114	5.761	0.01056	0.01921	0.07909
orz[1,6,7]	0.4285	0.1541	0.002083	0.2062	0.4039
orz[1,6,8]	0.2519	0.4052	0.001816	0.1016	0.2311
orz[1,7,8]	0.6541	9.663	0.01954	0.2304	0.5696
sd	0.1618	0.123	0.002106	0.007746	0.1367
totresdev	66.83	10.84	0.05295	49.31	66.17

or: Duration of treatment ≤4 weeks orz: Duration of treatment >4 weeks

d. Principle of acupoint selection

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	0.03398	0.6015	0.006248	-1.168	0.03928	1.201
SUCRA[1]	0.1684	0.129	0.002071	0	0.1429	0.4286
SUCRA[2]	0.59	0.05747	6.03E-04	0.5714	0.5714	0.7143
SUCRA[3]	0.2567	0.1106	0.001326	0	0.2857	0.4286
SUCRA[4]	0.3613	0.1282	0.001391	0	0.4286	0.4286
SUCRA[5]	0.07463	0.1186	0.001249	0	0	0.4286
SUCRA[6]	0.6928	0.05377	5.77E-04	0.5714	0.7143	0.7143
SUCRA[7]	0.8576	0.01927	7.89E-05	0.8571	0.8571	0.8571
SUCRA[8]	0.9985	0.0147	6.75E-05	1	1	1
SUCRAz[1]	0.1913	0.1575	9.49E-04	0	0.1429	0.4286
SUCRAz[2]	0.5894	0.05818	6.04E-04	0.4286	0.5714	0.7143
SUCRAz[3]	0.2421	0.1104	9.33E-04	0	0.2857	0.4286
SUCRAz[4]	0.3498	0.1295	0.001291	0	0.4286	0.4286
SUCRAz[5]	0.07876	0.1146	9.56E-04	0	0	0.4286
SUCRAz[6]	0.6925	0.05464	5.80E-04	0.5714	0.7143	0.7143
SUCRAz[7]	0.8576	0.01929	7.90E-05	0.8571	0.8571	0.8571
SUCRAz[8]	0.9985	0.01469	6.74E-05	1	1	1
or[1,2]	0.2513	0.0743	0.001339	0.1364	0.2425	0.4204
or[1,3]	0.889	0.3204	0.005348	0.4287	0.8433	1.641
or[1,4]	0.6901	0.407	0.00575	0.2131	0.5967	1.707
or[1,5]	1.493	0.7982	0.01178	0.4774	1.329	3.485
or[1,6]	0.1999	0.08491	0.001237	0.09374	0.1888	0.3689
or[1,7]	0.08207	0.04213	5.89E-04	0.03097	0.07517	0.1741
or[1,8]	0.02747	0.04339	2.18E-04	0.01094	0.02523	0.05609
or[2,3]	3.551	0.7407	0.008502	2.33	3.462	5.233
or[2,4]	2.775	1.437	0.01672	1.007	2.475	6.332
or[2,5]	5.979	2.699	0.03351	2.313	5.463	12.65
or[2,6]	0.8028	0.208	0.002513	0.4784	0.7789	1.262
or[2,7]	0.3276	0.1156	0.001253	0.1544	0.3109	0.5989
or[2,8]	0.109	0.05713	4.18E-04	0.05611	0.1044	0.1886
or[3,4]	0.8041	0.4324	0.005088	0.2781	0.7103	1.889

or[3,5]	1.713	0.7541	0.008587	0.6707	1.581	3.596
or[3,6]	0.2349	0.7887	0.001689	0.1263	0.2242	0.3942
or[3,7]	0.09423	0.09234	3.77E-04	0.04463	0.0894	0.1701
or[3,8]	0.03311	0.6017	0.001145	0.0143	0.03011	0.06078
or[4,5]	2.625	1.71	0.02052	0.6644	2.194	7.041
or[4,6]	0.3431	0.4367	0.001749	0.1351	0.316	0.6993
or[4,7]	0.141	0.08781	8.01E-04	0.04561	0.1251	0.3261
or[4,8]	0.04962	0.3171	7.03E-04	0.01362	0.04201	0.1241
or[5,6]	0.1706	7.322	0.01344	0.05996	0.1433	0.3357
or[5,7]	0.06627	0.8071	0.001517	0.02069	0.05651	0.1578
or[5,8]	0.03222	5.603	0.01025	0.006701	0.01908	0.05439
or[6,7]	0.4239	0.1611	0.001658	0.1921	0.3977	0.8113
or[6,8]	0.1442	0.0593	6.76E-04	0.06088	0.1338	0.2889
or[7,8]	0.3745	0.1882	0.001956	0.1364	0.3362	0.8375
orz[1,1,2]	0.2864	0.1615	7.63E-04	0.08576	0.2518	0.6888
orz[1,1,3]	1.017	0.6175	0.003647	0.2791	0.8739	2.587
orz[1,1,4]	0.7946	0.6595	0.005175	0.1531	0.6214	2.461
orz[1,1,5]	1.71	1.297	0.0104	0.3455	1.378	5.013
orz[1,1,6]	0.2298	0.1483	9.25E-04	0.0604	0.196	0.5969
orz[1,1,7]	0.09383	0.06673	4.38E-04	0.02175	0.07771	0.2594
orz[1,1,8]	0.03131	0.06027	1.89E-04	0.007635	0.02611	0.0839
orz[1,2,3]	3.551	0.7407	0.008502	2.33	3.462	5.233
orz[1,2,4]	2.775	1.437	0.01672	1.007	2.475	6.332
orz[1,2,5]	5.979	2.699	0.03351	2.313	5.463	12.65
orz[1,2,6]	0.8028	0.208	0.002513	0.4784	0.7789	1.262
orz[1,2,7]	0.3276	0.1156	0.001253	0.1544	0.3109	0.5989
orz[1,2,8]	0.109	0.05713	4.18E-04	0.05611	0.1044	0.1886
orz[1,3,4]	0.8041	0.4324	0.005088	0.2781	0.7103	1.889
orz[1,3,5]	1.713	0.7541	0.008587	0.6707	1.581	3.596
orz[1,3,6]	0.2349	0.7887	0.001689	0.1263	0.2242	0.3942
orz[1,3,7]	0.09423	0.09234	3.77E-04	0.04463	0.0894	0.1701
orz[1,3,8]	0.03311	0.6017	0.001145	0.0143	0.03011	0.06078
orz[1,4,5]	2.625	1.71	0.02052	0.6644	2.194	7.041
orz[1,4,6]	0.3431	0.4367	0.001749	0.1351	0.316	0.6993
orz[1,4,7]	0.141	0.08781	8.01E-04	0.04561	0.1251	0.3261
orz[1,4,8]	0.04962	0.3171	7.03E-04	0.01362	0.04201	0.1241
orz[1,5,6]	0.1706	7.322	0.01344	0.05996	0.1433	0.3357
orz[1,5,7]	0.06627	0.8071	0.001517	0.02069	0.05651	0.1578
orz[1,5,8]	0.03222	5.603	0.01025	0.006701	0.01908	0.05439
orz[1,6,7]	0.4239	0.1611	0.001658	0.1921	0.3977	0.8113
orz[1,6,8]	0.1442	0.0593	6.76E-04	0.06088	0.1338	0.2889
orz[1,7,8]	0.3745	0.1882	0.001956	0.1364	0.3362	0.8375
sd	0.2694	0.1708	0.003203	0.01371	0.2561	0.6327

or: fixed points orz: semi-fixed points

e.gender						
	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	-12.54	10.77	0.3495	-33.26	-8.802	1.822
SUCRA[1]	0.8475	0.3124	0.01001	0	1	1
SUCRA[2]	0.4688	0.07754	0.001726	0.4286	0.4286	0.7143
SUCRA[3]	0.1733	0.09208	0.001542	0	0.1429	0.2857
SUCRA[4]	0.2574	0.1047	0.001729	0	0.2857	0.4286
SUCRA[5]	0.04337	0.08379	0.001298	0	0	0.2857
SUCRA[6]	0.5748	0.07572	0.001734	0.4286	0.5714	0.7143
SUCRA[7]	0.7437	0.06053	0.001821	0.7143	0.7143	0.8571
SUCRA[8]	0.891	0.06314	0.00194	0.8571	0.8571	1
SUCRAz[1]	0.1746	0.1261	0.001006	0	0.1429	0.4286
SUCRAz[2]	0.5894	0.05682	5.47E-04	0.5714	0.5714	0.7143
SUCRAz[3]	0.2578	0.1117	0.001043	0	0.2857	0.4286
SUCRAz[4]	0.3591	0.1297	0.001456	0	0.4286	0.4286
SUCRAz[5]	0.06943	0.1171	0.001119	0	0	0.4286
SUCRAz[6]	0.6934	0.05305	5.09E-04	0.5714	0.7143	0.7143
SUCRAz[7]	0.8576	0.01829	1.05E-04	0.8571	0.8571	0.8571
SUCRAz[8]	0.9986	0.01408	9.64E-05	1	1	1
or[1,2]	5.54E+12	3.14E+13	9.52E+11	0.04145	1591	6.75E+13
or[1,3]	1.91E+13	1.08E+14	3.26E+12	0.1449	5374	2.40E+14
or[1,4]	1.57E+13	9.82E+13	2.73E+12	0.09924	4259	1.71E+14
or[1,5]	3.27E+13	1.97E+14	5.50E+12	0.2138	9288	3.60E+14
or[1,6]	4.42E+12	2.55E+13	7.61E+11	0.0325	1220	5.32E+13
or[1,7]	1.82E+12	1.09E+13	3.14E+11	0.01276	488.1	2.11E+13
or[1,8]	6.12E+11	3.60E+12	1.06E+11	0.0042	169.5	7.25E+12
or[2,3]	3.532	0.7362	0.008387	2.312	3.458	5.197
or[2,4]	2.786	1.412	0.01813	1.008	2.488	6.283
or[2,5]	5.983	2.665	0.03439	2.35	5.455	12.62
or[2,6]	0.8015	0.2029	0.0024	0.4775	0.781	1.246
or[2,7]	0.3297	0.1144	0.001279	0.1565	0.3127	0.5968
or[2,8]	0.1095	0.05039	4.42E-04	0.0571	0.1045	0.1894
or[3,4]	0.8133	0.4292	0.005553	0.2818	0.7209	1.885
or[3,5]	1.726	0.7557	0.009537	0.6812	1.59	3.577
or[3,6]	0.236	0.8484	0.001762	0.1267	0.226	0.3941
or[3,7]	0.09551	0.09196	4.38E-04	0.04512	0.09058	0.1719
or[3,8]	0.0335	0.617	0.00117	0.01468	0.03031	0.06186
or[4,5]	2.602	1.662	0.01973	0.6807	2.199	6.867
or[4,6]	0.3411	0.5388	0.001955	0.1354	0.3138	0.6979
or[4,7]	0.141	0.09074	8.26E-04	0.04629	0.1257	0.324
or[4,8]	0.04944	0.3795	7.77E-04	0.01386	0.04216	0.1222
or[5,6]	0.1719	8.49	0.01555	0.05987	0.1435	0.3315
or[5,7]	0.0663	0.8639	0.001639	0.02116	0.05685	0.1551


orz[5,8]	0.03322	6.19	0.01132	0.006954	0.01921	0.05293
orz[6,7]	0.4271	0.1601	0.001702	0.1954	0.4	0.8144
orz[6,8]	0.1449	0.05885	7.23E-04	0.06273	0.1345	0.2869
orz[7,8]	0.3726	0.1828	0.002078	0.1391	0.3354	0.8257
orz[1,1,2]	0.2551	0.06534	3.09E-04	0.1512	0.2484	0.3967
orz[1,1,3]	0.8991	0.289	0.002354	0.4593	0.8577	1.578
orz[1,1,4]	0.7066	0.3985	0.004629	0.2251	0.6167	1.705
orz[1,1,5]	1.521	0.7801	0.008931	0.5107	1.358	3.477
orz[1,1,6]	0.2031	0.07266	6.06E-04	0.1002	0.1936	0.3595
orz[1,1,7]	0.08396	0.03875	3.35E-04	0.03339	0.07753	0.1713
orz[1,1,8]	0.02802	0.03959	1.45E-04	0.01191	0.02596	0.05513
orz[1,2,3]	3.532	0.7362	0.008387	2.312	3.458	5.197
orz[1,2,4]	2.786	1.412	0.01813	1.008	2.488	6.283
orz[1,2,5]	5.983	2.665	0.03439	2.35	5.455	12.62
orz[1,2,6]	0.8015	0.2029	0.0024	0.4775	0.781	1.246
orz[1,2,7]	0.3297	0.1144	0.001279	0.1565	0.3127	0.5968
orz[1,2,8]	0.1095	0.05039	4.42E-04	0.0571	0.1045	0.1894
orz[1,3,4]	0.8133	0.4292	0.005553	0.2818	0.7209	1.885
orz[1,3,5]	1.726	0.7557	0.009537	0.6812	1.59	3.577
orz[1,3,6]	0.236	0.8484	0.001762	0.1267	0.226	0.3941
orz[1,3,7]	0.09551	0.09196	4.38E-04	0.04512	0.09058	0.1719
orz[1,3,8]	0.0335	0.617	0.00117	0.01468	0.03031	0.06186
orz[1,4,5]	2.602	1.662	0.01973	0.6807	2.199	6.867
orz[1,4,6]	0.3411	0.5388	0.001955	0.1354	0.3138	0.6979
orz[1,4,7]	0.141	0.09074	8.26E-04	0.04629	0.1257	0.324
orz[1,4,8]	0.04944	0.3795	7.77E-04	0.01386	0.04216	0.1222
orz[1,5,6]	0.1719	8.49	0.01555	0.05987	0.1435	0.3315
orz[1,5,7]	0.0663	0.8639	0.001639	0.02116	0.05685	0.1551
orz[1,5,8]	0.03322	6.19	0.01132	0.006954	0.01921	0.05293
orz[1,6,7]	0.4271	0.1601	0.001702	0.1954	0.4	0.8144
orz[1,6,8]	0.1449	0.05885	7.23E-04	0.06273	0.1345	0.2869
orz[1,7,8]	0.3726	0.1828	0.002078	0.1391	0.3354	0.8257
sd	0.2533	0.1645	0.003102	0.0134	0.2381	0.6073
totresdev	91.28	12.58	0.07884	69.31	90.89	115.4

Gender ratio=(n[female] x 2+ n[male] x1)/n[total]


orz: Gender ratio≤1.5 orz: Gender ratio>1.5

4.3 FS-14 total score of CFS patients

A.Network map




B. Contribution plot



A- Acupuncture with moxibustion; B- Acupuncture; C- Moxibustion; D- Acupuncture with THM; E- Moxibustion with THM; F- Traditional Chinese herbal medicine (THM); G- Western medicine; H- No control

C. Convergence diagram



Potential scale reduction factors:

	Point est.	Upper C.I.
d.2.1	1	1
d.2.3	1	1
d.2.5	1	1
d.2.6	1	1
d.2.7	1	1
d.2.8	1	1
d.6.4	1	1
sd.d	1	1

1- Acupuncture with moxibustion; 2- Acupuncture; 3- Moxibustion; 4- Acupuncture with THM; 5- Moxibustion with THM; 6- Traditional Chinese herbal medicine (THM); 7- Western medicine; 8- No control

D. Trajectories and density diagram

Results on the Log Odds Ratio scale

Iterations = 10010:60000

Thinning interval = 10

Number of chains = 4

Sample size per chain = 5000

1. Empirical mean and standard deviation for each variable, plus standard error of the mean:

	Mean	SD	NaiveSE	Time-seriesSE
d.2.1	2.1982	0.5710	0.004038	0.004071
d.2.3	1.4150	0.6139	0.004341	0.004341
d.2.5	1.5191	1.0460	0.007396	0.007273
d.2.6	-0.8948	0.6969	0.004928	0.005005
d.2.7	-1.7984	0.9720	0.006873	0.006941
d.2.8	-2.2637	0.5062	0.003579	0.003458
d.6.4	1.4716	1.0965	0.007753	0.007632
sd.d	1.4713	0.2515	0.001779	0.001815


2. Quantiles for each variable:


	2.5%	25%	50%	75%	97.5%
d.2.1	1.0576	1.8269	2.2013	2.5741	3.3223
d.2.3	0.2008	1.0155	1.4152	1.8106	2.6369
d.2.5	-0.5408	0.8280	1.5180	2.1994	3.6033
d.2.6	-2.2805	-1.3491	-0.8959	-0.4428	0.4921
d.2.7	-3.7187	-2.4343	-1.8050	-1.1640	0.1164
d.2.8	-3.2670	-2.5937	-2.2598	-1.9270	-1.2856
d.6.4	-0.7006	0.7556	1.4717	-2.1788	3.6355
sd.d	1.0649	1.2929	1.4401	1.6172	2.0552

3. Model fit (residual deviance):

Dbar: 68.54744 pD: 61.98776 DIC:130.53520


65 data points, ratio 1.055, I²= 7%





E. Forest plot

Compared with No Control group



F . League table

Acupuncture with moxibustion					
9.04 (2.88, 27.73)	Acupuncture				
2.2 (0.5, 9.5)	0.24 (0.07, 0.82)	Moxibustion			
5 (0.38, 65.46)	0.56 (0.04, 7.35)	2.3 (0.14, 38.67)	Acupuncture with THM		
1.98 (0.22, 17.3)	0.22 (0.03, 1.72)	0.9 (0.09, 9.59)	0.39 (0.02, 7.03)	Moxibustion with THM	
22.08 (5.28, ...)	2.45 (0.61, ...)	9.96 (1.76, ...)	4.36 (0.5, ...)	11 (1.77, ...)	Traditional

91.55)	9.78)	59.3)	37.92)	71.79)	Chinses herbal medicine		
54.61 (6.33, 445.72)	6.08 (0.89, 41.21)	24.88 (4.12, 151.54)	10.91 (0.43, 256.78)	27.79 (1.61, 456.6)	2.49 (0.24, 24.35)	Western medicine	
86.56 (20.2, 364.67)	9.58 (3.62, 26.23)	39.42 (8.57, 189.2)	16.96 (1.11, 265.34)	43.5 (4.61, 441.68)	3.91 (0.76, 21.41)	1.57 (0.19, 13.94)	No control

G. Inconsistency and Heterogeneity

a. Loops of Statistical Inconsistency:

Loop	IF	self	z_value	p_value	CI_95	Loop_Heterog_tau ²
AM-Acu-Mox	2.065	1.619	1.279	0.202	(0.00,5.24)	2.523
AM-Acu-NC	2.054	2.096	0.980	0.327	(0.00,6.16)	2.309
AM-Acu-THM	1.077	2.110	0.510	0.610	(0.00,5.21)	4.659
Acu-MT-THM	0.433	3.406	0.127	0.899	(0.00,7.11)	5.810
Acu-Mox-WM	0.304	1.335	0.228	0.820	(0.00,2.92)	0.694

b. Side-splitting

Side	Direct		Indirect		Difference		P> z	tau
	Coef.	Std. Err.	Coef.	Std. Err.	Coef.	Std. Err.		
A B	-2.305951	.65426	-1.97746	.9845388	-.3284915	1.18225	0.781	1.418279
A C	-2.126021	.993292	.2812497	.8944823	-2.407271	1.336896	0.072	1.329197
A F	-2.357591	.8187938	-4.386167	1.079052	2.028576	1.354578	0.134	1.344323
A H	-2.667148	1.482368	-4.928846	.7640266	2.261697	1.668503	0.175	1.366883
B C	1.83649	.6686422	.2622648	1.111815	1.574225	1.297659	0.225	1.380465
B E	1.5	1.678761	1.527036	1.250325	-.0270358	2.093216	0.990	1.416971
B F	-1.349406	.8468539	-.2186542	1.027484	-1.130752	1.331299	0.396	1.395591
B G	-1.77	1.445186	-1.833633	1.189895	.063633	1.872008	0.973	1.423544
B H*	-2.351019	.4745794	1.534789	2.766528	-3.885808	2.803832	0.166	1.361341
C G	-3.24678	1.01286	-3.182878	1.574323	-.0639014	1.872002	0.973	1.423544
D F*	-1.478334	1.029831	-6.201754	745.4444	4.723421	745.4451	0.995	1.387736
E F	-2.417179	1.034031	-2.390207	1.820086	-.0269724	2.093213	0.990	1.416972


* All the evidence about these contrasts comes from the trials which directly compare them.

c. Design-by-treatment test

chi2(10) = 9.31


Prob > chi2 = 0.5026

H. Comparison-adjusted funnel plot




I.SUCRA diagram

a. Ranking probability diagram



b. Cumulative probability ranking diagram



AM-Acupuncture with moxibustion; A-Acupuncture; M-Moxibustion; AT-Acupuncture with THM; MT-Moxibustion with THM; T-Traditional Chinese herbal medicine; W-Western medicine; NC-No control.

J. Subgroup analysis

a. age

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	-1.167	1.191	0.02507	-3.54	-1.163	1.181
MD[1,2]	-1.911	0.6481	0.006934	-3.182	-1.915	-0.6184
MD[1,3]	-0.3874	0.8442	0.009023	-2.039	-0.3915	1.299
MD[1,4]	-1.315	1.356	0.007634	-3.996	-1.314	1.368
MD[1,5]	-0.3865	1.15	0.007442	-2.648	-0.3907	1.896
MD[1,6]	-2.793	0.7845	0.007178	-4.343	-2.794	-1.237
MD[1,7]	-3.65	1.136	0.008533	-5.881	-3.657	-1.385
MD[1,8]	-4.194	0.7896	0.006656	-5.763	-4.191	-2.642
MD[2,3]	1.524	0.6249	0.002443	0.2937	1.522	2.764
MD[2,4]	0.5966	1.307	0.002718	-1.995	0.5992	3.176
MD[2,5]	1.525	1.053	0.002283	-0.5592	1.527	3.608
MD[2,6]	-0.8821	0.699	0.001606	-2.273	-0.8772	0.491
MD[2,7]	-1.739	0.9677	0.002267	-3.652	-1.741	0.1794
MD[2,8]	-2.282	0.5101	0.001063	-3.306	-2.276	-1.29
MD[3,4]	-0.9272	1.423	0.003515	-3.749	-0.9238	1.879

MD[3,5]	9.63E-04	1.204	0.003262	-2.384	0.002439	2.375
MD[3,6]	-2.406	0.8976	0.002759	-4.201	-2.402	-0.6418
MD[3,7]	-3.263	0.897	0.00151	-5.042	-3.262	-1.494
MD[3,8]	-3.806	0.8025	0.003063	-5.411	-3.797	-2.239
MD[4,5]	0.9282	1.454	0.002435	-1.935	0.9236	3.808
MD[4,6]	-1.479	1.104	0.001836	-3.661	-1.479	0.7025
MD[4,7]	-2.336	1.612	0.00352	-5.514	-2.338	0.8516
MD[4,8]	-2.879	1.395	0.003042	-5.657	-2.875	-0.1359
MD[5,6]	-2.407	0.9455	0.001563	-4.289	-2.405	-0.5464
MD[5,7]	-3.264	1.419	0.003213	-6.057	-3.267	-0.4441
MD[5,8]	-3.807	1.163	0.00262	-6.127	-3.801	-1.528
MD[6,7]	-0.857	1.173	0.00274	-3.167	-0.8621	1.478
MD[6,8]	-1.4	0.8522	0.00207	-3.1	-1.397	0.2735
MD[7,8]	-0.5433	1.093	0.002805	-2.732	-0.5353	1.599
MDz[1,1,2]	-3.078	1.061	0.01867	-5.187	-3.08	-0.971
MDz[1,1,3]	-1.555	1.083	0.01656	-3.695	-1.555	0.604
MDz[1,1,4]	-2.482	1.586	0.01847	-5.623	-2.481	0.6535
MDz[1,1,5]	-1.554	1.417	0.01857	-4.361	-1.551	1.247
MDz[1,1,6]	-3.961	1.139	0.01841	-6.227	-3.958	-1.71
MDz[1,1,7]	-4.818	1.355	0.01736	-7.497	-4.819	-2.124
MDz[1,1,8]	-5.361	1.173	0.01914	-7.703	-5.354	-3.055
MDz[1,2,3]	1.524	0.6249	0.002443	0.2937	1.522	2.764
MDz[1,2,4]	0.5966	1.307	0.002718	-1.995	0.5992	3.176
MDz[1,2,5]	1.525	1.053	0.002283	-0.5592	1.527	3.608
MDz[1,2,6]	-0.8821	0.699	0.001606	-2.273	-0.8772	0.491
MDz[1,2,7]	-1.739	0.9677	0.002267	-3.652	-1.741	0.1794
MDz[1,2,8]	-2.282	0.5101	0.001063	-3.306	-2.276	-1.29
MDz[1,3,4]	-0.9272	1.423	0.003515	-3.749	-0.9238	1.879
MDz[1,3,5]	9.63E-04	1.204	0.003262	-2.384	0.002439	2.375
MDz[1,3,6]	-2.406	0.8976	0.002759	-4.201	-2.402	-0.6418
MDz[1,3,7]	-3.263	0.897	0.00151	-5.042	-3.262	-1.494
MDz[1,3,8]	-3.806	0.8025	0.003063	-5.411	-3.797	-2.239
MDz[1,4,5]	0.9282	1.454	0.002435	-1.935	0.9236	3.808
MDz[1,4,6]	-1.479	1.104	0.001836	-3.661	-1.479	0.7025
MDz[1,4,7]	-2.336	1.612	0.00352	-5.514	-2.338	0.8516
MDz[1,4,8]	-2.879	1.395	0.003042	-5.657	-2.875	-0.1359
MDz[1,5,6]	-2.407	0.9455	0.001563	-4.289	-2.405	-0.5464
MDz[1,5,7]	-3.264	1.419	0.003213	-6.057	-3.267	-0.4441
MDz[1,5,8]	-3.807	1.163	0.00262	-6.127	-3.801	-1.528
MDz[1,6,7]	-0.857	1.173	0.00274	-3.167	-0.8621	1.478
MDz[1,6,8]	-1.4	0.8522	0.00207	-3.1	-1.397	0.2735
MDz[1,7,8]	-0.5433	1.093	0.002805	-2.732	-0.5353	1.599
SUCRA[1]	0.1206	0.1277	0.001116	0	0.1429	0.4286
SUCRA[2]	0.5333	0.1029	2.10E-04	0.2857	0.5714	0.7143

SUCRA[3]	0.2072	0.1431	7.49E-04	0	0.1429	0.4286
SUCRA[4]	0.4043	0.2187	4.39E-04	0	0.4286	0.8571
SUCRA[5]	0.212	0.1745	4.15E-04	0	0.1429	0.5714
SUCRA[6]	0.7252	0.101	1.92E-04	0.5714	0.7143	1
SUCRA[7]	0.851	0.1363	3.20E-04	0.5714	0.8571	1
SUCRA[8]	0.9464	0.08167	1.77E-04	0.7143	1	1
SUCRAz[1]	0.03786	0.0885	0.001098	0	0	0.2857
SUCRAz[2]	0.5333	0.1029	2.28E-04	0.2857	0.5714	0.7143
SUCRAz[3]	0.2418	0.1188	3.46E-04	0	0.2857	0.4286
SUCRAz[4]	0.4191	0.2007	4.59E-04	0	0.4286	0.8571
SUCRAz[5]	0.2452	0.1516	5.83E-04	0	0.2857	0.5714
SUCRAz[6]	0.7251	0.101	1.94E-04	0.5714	0.7143	1
SUCRAz[7]	0.8512	0.1357	3.14E-04	0.5714	0.8571	1
SUCRAz[8]	0.9464	0.08169	1.78E-04	0.7143	1	1
sd	1.478	0.2588	0.001345	1.063	1.446	2.073
totresdev	68.36	11.55	0.02525	47.55	67.72	92.7

or: Average age ≤40 years orz: Average age >40 years

b. course of disease

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	-0.3858	1.087	0.02681	-2.48	-0.4104	1.829
MD[1,2]	-2.008	0.7975	0.01373	-3.595	-2.006	-0.434
MD[1,3]	-0.6369	0.8588	0.01054	-2.328	-0.6374	1.069
MD[1,4]	-1.403	1.472	0.01541	-4.308	-1.402	1.502
MD[1,5]	-0.4763	1.268	0.01501	-2.987	-0.4754	2.03
MD[1,6]	-2.882	0.9483	0.01519	-4.768	-2.879	-1.014
MD[1,7]	-3.849	1.186	0.01177	-6.189	-3.849	-1.494
MD[1,8]	-4.287	0.9054	0.01295	-6.092	-4.281	-2.511
MD[2,3]	1.371	0.6402	0.00347	0.1097	1.369	2.641
MD[2,4]	0.6048	1.333	0.003202	-2.026	0.6067	3.238
MD[2,5]	1.532	1.071	0.002567	-0.593	1.532	3.644
MD[2,6]	-0.8738	0.7129	0.00218	-2.287	-0.8719	0.5299
MD[2,7]	-1.841	0.9887	0.002752	-3.801	-1.843	0.1227
MD[2,8]	-2.279	0.5193	0.00127	-3.321	-2.274	-1.269
MD[3,4]	-0.7662	1.458	0.005702	-3.651	-0.765	2.116
MD[3,5]	0.1605	1.23	0.005159	-2.278	0.1632	2.587
MD[3,6]	-2.245	0.9278	0.005158	-4.086	-2.24	-0.4254
MD[3,7]	-3.212	0.9141	0.001743	-5.026	-3.212	-1.399
MD[3,8]	-3.65	0.8125	0.002876	-5.281	-3.642	-2.065
MD[4,5]	0.9268	1.48	0.002659	-1.989	0.9241	3.859
MD[4,6]	-1.479	1.125	0.001933	-3.709	-1.478	0.742
MD[4,7]	-2.446	1.646	0.004998	-5.699	-2.448	0.8181
MD[4,8]	-2.884	1.423	0.003905	-5.712	-2.88	-0.09264
MD[5,6]	-2.405	0.9615	0.001737	-4.307	-2.405	-0.5066

MD[5,7]	-3.373	1.445	0.004427	-6.231	-3.372	-0.5063
MD[5,8]	-3.811	1.185	0.003278	-6.165	-3.805	-1.481
MD[6,7]	-0.9677	1.203	0.004383	-3.339	-0.9697	1.42
MD[6,8]	-1.405	0.8715	0.003089	-3.14	-1.402	0.3025
MD[7,8]	-0.4377	1.111	0.002364	-2.661	-0.4309	1.741
MDz[1,1,2]	-2.394	0.799	0.01344	-3.959	-2.401	-0.7854
MDz[1,1,3]	-1.023	1.013	0.0167	-3.003	-1.031	1.01
MDz[1,1,4]	-1.789	1.429	0.01223	-4.611	-1.792	1.047
MDz[1,1,5]	-0.8621	1.231	0.01252	-3.29	-0.8639	1.579
MDz[1,1,6]	-3.267	0.8796	0.01201	-4.997	-3.271	-1.518
MDz[1,1,7]	-4.235	1.266	0.01568	-6.731	-4.239	-1.708
MDz[1,1,8]	-4.673	0.948	0.01434	-6.548	-4.674	-2.794
MDz[1,2,3]	1.371	0.6402	0.00347	0.1097	1.369	2.641
MDz[1,2,4]	0.6048	1.333	0.003202	-2.026	0.6067	3.238
MDz[1,2,5]	1.532	1.071	0.002567	-0.593	1.532	3.644
MDz[1,2,6]	-0.8738	0.7129	0.00218	-2.287	-0.8719	0.5299
MDz[1,2,7]	-1.841	0.9887	0.002752	-3.801	-1.843	0.1227
MDz[1,2,8]	-2.279	0.5193	0.00127	-3.321	-2.274	-1.269
MDz[1,3,4]	-0.7662	1.458	0.005702	-3.651	-0.765	2.116
MDz[1,3,5]	0.1605	1.23	0.005159	-2.278	0.1632	2.587
MDz[1,3,6]	-2.245	0.9278	0.005158	-4.086	-2.24	-0.4254
MDz[1,3,7]	-3.212	0.9141	0.001743	-5.026	-3.212	-1.399
MDz[1,3,8]	-3.65	0.8125	0.002876	-5.281	-3.642	-2.065
MDz[1,4,5]	0.9268	1.48	0.002659	-1.989	0.9241	3.859
MDz[1,4,6]	-1.479	1.125	0.001933	-3.709	-1.478	0.742
MDz[1,4,7]	-2.446	1.646	0.004998	-5.699	-2.448	0.8181
MDz[1,4,8]	-2.884	1.423	0.003905	-5.712	-2.88	-0.09264
MDz[1,5,6]	-2.405	0.9615	0.001737	-4.307	-2.405	-0.5066
MDz[1,5,7]	-3.373	1.445	0.004427	-6.231	-3.372	-0.5063
MDz[1,5,8]	-3.811	1.185	0.003278	-6.165	-3.805	-1.481
MDz[1,6,7]	-0.9677	1.203	0.004383	-3.339	-0.9697	1.42
MDz[1,6,8]	-1.405	0.8715	0.003089	-3.14	-1.402	0.3025
MDz[1,7,8]	-0.4377	1.111	0.002364	-2.661	-0.4309	1.741
SUCRA[1]	0.1066	0.1291	0.001599	0	0	0.4286
SUCRA[2]	0.5313	0.1055	2.37E-04	0.2857	0.5714	0.7143
SUCRA[3]	0.2362	0.1395	3.28E-04	0	0.2857	0.4286
SUCRA[4]	0.3974	0.2227	7.71E-04	0	0.4286	0.8571
SUCRA[5]	0.2072	0.174	8.90E-04	0	0.1429	0.5714
SUCRA[6]	0.72	0.103	3.21E-04	0.5714	0.7143	1
SUCRA[7]	0.861	0.1345	3.68E-04	0.5714	0.8571	1
SUCRA[8]	0.9403	0.08427	1.51E-04	0.7143	1	1
SUCRAz[1]	0.07005	0.1089	0.001371	0	0	0.2857
SUCRAz[2]	0.532	0.1047	2.38E-04	0.2857	0.5714	0.7143
SUCRAz[3]	0.2466	0.1361	0.001027	0	0.2857	0.4286

SUCRAz[4]	0.4063	0.2128	4.27E-04	0	0.4286	0.8571
SUCRAz[5]	0.2235	0.1638	3.96E-04	0	0.1429	0.5714
SUCRAz[6]	0.7202	0.1025	3.04E-04	0.5714	0.7143	1
SUCRAz[7]	0.861	0.1344	3.79E-04	0.5714	0.8571	1
SUCRAz[8]	0.9403	0.08428	1.51E-04	0.7143	1	1
sd	1.505	0.2631	0.001504	1.081	1.474	2.106
totresdev	68.49	11.6	0.02511	47.6	67.84	92.98

or: Average course of disease ≤ 1 year orz: Average course of disease > 1 year

c. Duration of treatment

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	11.88	30.43	0.8308	-32.55	2.596	61.34
MD[1,2]	-14.41	30.43	0.8307	-63.93	-5.129	30.11
MD[1,3]	-12.92	30.44	0.8307	-62.48	-3.645	31.64
MD[1,4]	-13.07	30.45	0.8306	-62.79	-3.863	31.72
MD[1,5]	-12.14	30.45	0.8305	-61.86	-2.921	32.66
MD[1,6]	-14.55	30.44	0.8307	-64.12	-5.294	30.07
MD[1,7]	-16.17	30.44	0.8306	-65.82	-6.925	28.5
MD[1,8]	-16.18	30.44	0.8307	-65.74	-6.917	28.41
MD[2,3]	1.491	0.5819	9.68E-04	0.382	1.49	2.607
MD[2,4]	1.336	1.333	0.003067	-1.262	1.341	3.912
MD[2,5]	2.267	1.379	0.003125	-0.2931	2.268	4.826
MD[2,6]	-0.1407	0.8493	0.002111	-1.807	-0.1372	1.504
MD[2,7]	-1.759	0.8793	0.001383	-3.487	-1.76	-0.02611
MD[2,8]	-1.769	0.5684	8.22E-04	-2.89	-1.771	-0.6431
MD[3,4]	-0.155	1.447	0.003329	-2.934	-0.1496	2.595
MD[3,5]	0.7757	1.499	0.003404	-1.97	0.7786	3.511
MD[3,6]	-1.632	1.01	0.002437	-3.567	-1.628	0.2737
MD[3,7]	-3.25	0.8255	0.00117	-4.861	-3.25	-1.646
MD[3,8]	-3.261	0.8081	0.001372	-4.822	-3.261	-1.7
MD[4,5]	0.9307	1.431	0.002151	-1.856	0.9313	3.725
MD[4,6]	-1.477	1.013	0.00155	-3.468	-1.475	0.512
MD[4,7]	-3.095	1.583	0.003428	-6.158	-3.101	-0.00696
MD[4,8]	-3.106	1.436	0.003248	-5.883	-3.11	-0.2996
MD[5,6]	-2.408	1.046	0.001638	-4.373	-2.406	-0.4678
MD[5,7]	-4.026	1.627	0.003511	-7.071	-4.028	-0.9657
MD[5,8]	-4.036	1.477	0.003285	-6.812	-4.038	-1.253
MD[6,7]	-1.618	1.201	0.002623	-3.948	-1.624	0.7424
MD[6,8]	-1.629	1.004	0.002343	-3.585	-1.634	0.3581
MD[7,8]	-0.01046	1.042	0.001663	-2.063	-0.01063	2.04
MDz[1,1,2]	-2.529	0.5765	0.001794	-3.604	-2.532	-1.442
MDz[1,1,3]	-1.038	0.7317	0.002063	-2.385	-1.044	0.3296
MDz[1,1,4]	-1.193	1.338	0.003392	-3.783	-1.192	1.387
MDz[1,1,5]	-0.2623	1.364	0.003362	-2.815	-0.2631	2.301

MDz[1,1,6]	-2.67	0.8579	0.002494	-4.331	-2.669	-1.022
MDz[1,1,7]	-4.288	1.005	0.002449	-6.224	-4.291	-2.337
MDz[1,1,8]	-4.299	0.77	0.002049	-5.77	-4.303	-2.809
MDz[1,2,3]	1.491	0.5819	9.68E-04	0.382	1.49	2.607
MDz[1,2,4]	1.336	1.333	0.003067	-1.262	1.341	3.912
MDz[1,2,5]	2.267	1.379	0.003125	-0.2931	2.268	4.826
MDz[1,2,6]	-0.1407	0.8493	0.002111	-1.807	-0.1372	1.504
MDz[1,2,7]	-1.759	0.8793	0.001383	-3.487	-1.76	-0.02611
MDz[1,2,8]	-1.769	0.5684	8.22E-04	-2.89	-1.771	-0.6431
MDz[1,3,4]	-0.155	1.447	0.003329	-2.934	-0.1496	2.595
MDz[1,3,5]	0.7757	1.499	0.003404	-1.97	0.7786	3.511
MDz[1,3,6]	-1.632	1.01	0.002437	-3.567	-1.628	0.2737
MDz[1,3,7]	-3.25	0.8255	0.00117	-4.861	-3.25	-1.646
MDz[1,3,8]	-3.261	0.8081	0.001372	-4.822	-3.261	-1.7
MDz[1,4,5]	0.9307	1.431	0.002151	-1.856	0.9313	3.725
MDz[1,4,6]	-1.477	1.013	0.00155	-3.468	-1.475	0.512
MDz[1,4,7]	-3.095	1.583	0.003428	-6.158	-3.101	-0.00696
MDz[1,4,8]	-3.106	1.436	0.003248	-5.883	-3.11	-0.2996
MDz[1,5,6]	-2.408	1.046	0.001638	-4.373	-2.406	-0.4678
MDz[1,5,7]	-4.026	1.627	0.003511	-7.071	-4.028	-0.9657
MDz[1,5,8]	-4.036	1.477	0.003285	-6.812	-4.038	-1.253
MDz[1,6,7]	-1.618	1.201	0.002623	-3.948	-1.624	0.7424
MDz[1,6,8]	-1.629	1.004	0.002343	-3.585	-1.634	0.3581
MDz[1,7,8]	-0.01046	1.042	0.001663	-2.063	-0.01063	2.04
SUCRA[1]	0.3825	0.4658	0.01262	0	0	1
SUCRA[2]	0.5554	0.1312	0.001881	0.2857	0.5714	0.7143
SUCRA[3]	0.2597	0.1404	0.001903	0	0.2857	0.5714
SUCRA[4]	0.3069	0.1826	0.00186	0	0.2857	0.7143
SUCRA[5]	0.1652	0.1445	0.001848	0	0.1429	0.4286
SUCRA[6]	0.6007	0.1385	0.001858	0.2857	0.5714	0.8571
SUCRA[7]	0.8595	0.1302	0.001805	0.5714	0.8571	1
SUCRA[8]	0.8701	0.1121	0.001812	0.7143	0.8571	1
SUCRAz[1]	0.09359	0.1074	2.71E-04	0	0	0.2857
SUCRAz[2]	0.6093	0.1108	2.48E-04	0.4286	0.5714	0.7143
SUCRAz[3]	0.3089	0.1315	2.92E-04	0	0.2857	0.5714
SUCRAz[4]	0.3402	0.1949	3.85E-04	0	0.2857	0.7143
SUCRAz[5]	0.167	0.1681	3.25E-04	0	0.1429	0.5714
SUCRAz[6]	0.6541	0.119	2.50E-04	0.4286	0.7143	0.8571
SUCRAz[7]	0.9082	0.1094	1.83E-04	0.5714	0.8571	1
SUCRAz[8]	0.9188	0.08837	1.41E-04	0.7143	0.8571	1
sd	1.327	0.2505	5.86E-04	0.9329	1.295	1.904
totresdev	69.81	5843	11.21	32.92	50.03	72.16

or: Duration of treatment≤4 weeks orz: Duration of treatment>4 weeks

d. Principle of acupoint selection

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	0.775	1.196	0.02359	-1.579	0.7619	3.158
MD[1,2]	-2.425	0.6717	0.007172	-3.748	-2.428	-1.092
MD[1,3]	-0.9488	0.7904	0.00563	-2.499	-0.9525	0.6224
MD[1,4]	-1.839	1.373	0.007323	-4.549	-1.84	0.8804
MD[1,5]	-0.9034	1.167	0.007286	-3.202	-0.9052	1.407
MD[1,6]	-3.314	0.7993	0.006995	-4.894	-3.315	-1.735
MD[1,7]	-4.194	1.122	0.006392	-6.398	-4.197	-1.961
MD[1,8]	-4.678	0.8085	0.006863	-6.291	-4.673	-3.093
MD[2,3]	1.476	0.6291	0.002018	0.2376	1.475	2.729
MD[2,4]	0.5866	1.32	0.002638	-2.026	0.5892	3.195
MD[2,5]	1.522	1.063	0.002026	-0.5754	1.523	3.62
MD[2,6]	-0.8893	0.7033	0.001501	-2.283	-0.8883	0.4976
MD[2,7]	-1.769	0.9775	0.001965	-3.706	-1.769	0.171
MD[2,8]	-2.253	0.5143	9.57E-04	-3.288	-2.247	-1.255
MD[3,4]	-0.8898	1.436	0.00324	-3.733	-0.8885	1.948
MD[3,5]	0.0454	1.213	0.002846	-2.363	0.04816	2.442
MD[3,6]	-2.366	0.9028	0.002414	-4.159	-2.364	-0.5853
MD[3,7]	-3.245	0.9071	0.001357	-5.05	-3.244	-1.448
MD[3,8]	-3.729	0.8036	0.001965	-5.338	-3.721	-2.16
MD[4,5]	0.9352	1.469	0.002454	-1.967	0.9352	3.843
MD[4,6]	-1.476	1.116	0.00178	-3.69	-1.475	0.7287
MD[4,7]	-2.355	1.629	0.00323	-5.572	-2.356	0.8755
MD[4,8]	-2.839	1.409	0.002844	-5.646	-2.835	-0.06485
MD[5,6]	-2.411	0.9549	0.001477	-4.306	-2.409	-0.5301
MD[5,7]	-3.29	1.434	0.002816	-6.125	-3.292	-0.4504
MD[5,8]	-3.775	1.175	0.002267	-6.114	-3.769	-1.468
MD[6,7]	-0.8793	1.183	0.002446	-3.215	-0.8811	1.466
MD[6,8]	-1.363	0.8593	0.00183	-3.077	-1.359	0.3242
MD[7,8]	-0.4842	1.099	0.002015	-2.687	-0.4754	1.671
MDz[1,1,2]	-1.65	1.035	0.01685	-3.684	-1.657	0.4117
MDz[1,1,3]	-0.1737	1.203	0.01855	-2.539	-0.1824	2.229
MDz[1,1,4]	-1.064	1.59	0.01732	-4.203	-1.064	2.081
MDz[1,1,5]	-0.1283	1.412	0.01711	-2.911	-0.1316	2.676
MDz[1,1,6]	-2.539	1.13	0.01708	-4.773	-2.54	-0.2947
MDz[1,1,7]	-3.419	1.419	0.01803	-6.212	-3.427	-0.5852
MDz[1,1,8]	-3.903	1.151	0.01731	-6.19	-3.9	-1.627
MDz[1,2,3]	1.476	0.6291	0.002018	0.2376	1.475	2.729
MDz[1,2,4]	0.5866	1.32	0.002638	-2.026	0.5892	3.195
MDz[1,2,5]	1.522	1.063	0.002026	-0.5754	1.523	3.62
MDz[1,2,6]	-0.8893	0.7033	0.001501	-2.283	-0.8883	0.4976
MDz[1,2,7]	-1.769	0.9775	0.001965	-3.706	-1.769	0.171
MDz[1,2,8]	-2.253	0.5143	9.57E-04	-3.288	-2.247	-1.255

MDz[1,3,4]	-0.8898	1.436	0.00324	-3.733	-0.8885	1.948
MDz[1,3,5]	0.0454	1.213	0.002846	-2.363	0.04816	2.442
MDz[1,3,6]	-2.366	0.9028	0.002414	-4.159	-2.364	-0.5853
MDz[1,3,7]	-3.245	0.9071	0.001357	-5.05	-3.244	-1.448
MDz[1,3,8]	-3.729	0.8036	0.001965	-5.338	-3.721	-2.16
MDz[1,4,5]	0.9352	1.469	0.002454	-1.967	0.9352	3.843
MDz[1,4,6]	-1.476	1.116	0.00178	-3.69	-1.475	0.7287
MDz[1,4,7]	-2.355	1.629	0.00323	-5.572	-2.356	0.8755
MDz[1,4,8]	-2.839	1.409	0.002844	-5.646	-2.835	-0.06485
MDz[1,5,6]	-2.411	0.9549	0.001477	-4.306	-2.409	-0.5301
MDz[1,5,7]	-3.29	1.434	0.002816	-6.125	-3.292	-0.4504
MDz[1,5,8]	-3.775	1.175	0.002267	-6.114	-3.769	-1.468
MDz[1,6,7]	-0.8793	1.183	0.002446	-3.215	-0.8811	1.466
MDz[1,6,8]	-1.363	0.8593	0.00183	-3.077	-1.359	0.3242
MDz[1,7,8]	-0.4842	1.099	0.002015	-2.687	-0.4754	1.671
SUCRA[1]	0.05898	0.09521	5.91E-04	0	0	0.2857
SUCRA[2]	0.5324	0.1028	1.98E-04	0.2857	0.5714	0.7143
SUCRA[3]	0.2405	0.1271	2.60E-04	0	0.2857	0.4286
SUCRA[4]	0.4146	0.2097	4.09E-04	0	0.4286	0.8571
SUCRA[5]	0.2316	0.164	4.32E-04	0	0.2857	0.5714
SUCRA[6]	0.7249	0.1022	1.82E-04	0.5714	0.7143	1
SUCRA[7]	0.8548	0.1366	2.62E-04	0.5714	0.8571	1
SUCRA[8]	0.9422	0.08416	1.47E-04	0.7143	1	1
SUCRAz[1]	0.1749	0.1754	0.002494	0	0.1429	0.5714
SUCRAz[2]	0.5245	0.1097	3.86E-04	0.2857	0.5714	0.7143
SUCRAz[3]	0.1939	0.1448	0.001035	0	0.1429	0.4286
SUCRAz[4]	0.3921	0.2263	6.11E-04	0	0.4286	0.8571
SUCRAz[5]	0.1961	0.1739	6.67E-04	0	0.1429	0.5714
SUCRAz[6]	0.7229	0.1052	2.18E-04	0.5714	0.7143	1
SUCRAz[7]	0.8534	0.1402	3.05E-04	0.5714	0.8571	1
SUCRAz[8]	0.9421	0.08442	1.49E-04	0.7143	1	1
sd	1.494	0.2614	0.001189	1.072	1.463	2.091
totresdev	68.52	11.59	0.02262	47.67	67.88	93

or: fixed points orz: semi-fixed points

e.gender

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	2.742	1.534	0.03951	-0.3032	2.712	5.906
MD[1,2]	-4.545	1.417	0.03423	-7.435	-4.528	-1.749
MD[1,3]	-3.23	1.534	0.03568	-6.341	-3.213	-0.2061
MD[1,4]	-4.138	1.878	0.03688	-7.921	-4.124	-0.454
MD[1,5]	-3.162	1.732	0.03616	-6.644	-3.149	0.2504
MD[1,6]	-5.617	1.565	0.03677	-8.809	-5.597	-2.539
MD[1,7]	-6.425	1.679	0.0352	-9.81	-6.413	-3.111

MD[1,8]	-6.818	1.497	0.03474	-9.875	-6.795	-3.886
MD[2,3]	1.315	0.583	0.001822	0.1687	1.313	2.473
MD[2,4]	0.4069	1.231	0.003639	-2.031	0.4083	2.84
MD[2,5]	1.383	0.9931	0.002836	-0.5771	1.382	3.352
MD[2,6]	-1.073	0.6619	0.002951	-2.388	-1.071	0.2312
MD[2,7]	-1.88	0.9049	0.00188	-3.669	-1.881	-0.08246
MD[2,8]	-2.273	0.479	0.001047	-3.24	-2.268	-1.343
MD[3,4]	-0.9077	1.333	0.003101	-3.556	-0.9041	1.721
MD[3,5]	0.06801	1.127	0.0025	-2.162	0.06875	2.299
MD[3,6]	-2.387	0.8373	0.002216	-4.05	-2.383	-0.7433
MD[3,7]	-3.195	0.8376	0.001359	-4.855	-3.195	-1.534
MD[3,8]	-3.588	0.7473	0.00184	-5.087	-3.581	-2.131
MD[4,5]	0.9757	1.367	0.002466	-1.727	0.9708	3.687
MD[4,6]	-1.48	1.037	0.001704	-3.534	-1.48	0.5715
MD[4,7]	-2.287	1.509	0.003545	-5.268	-2.287	0.7023
MD[4,8]	-2.68	1.314	0.003484	-5.296	-2.674	-0.09592
MD[5,6]	-2.455	0.8902	0.001644	-4.226	-2.453	-0.7074
MD[5,7]	-3.263	1.329	0.002909	-5.891	-3.263	-0.634
MD[5,8]	-3.656	1.095	0.002772	-5.844	-3.648	-1.51
MD[6,7]	-0.8073	1.095	0.002839	-2.965	-0.8093	1.369
MD[6,8]	-1.201	0.8028	0.002779	-2.8	-1.197	0.3744
MD[7,8]	-0.3934	1.02	0.002021	-2.437	-0.3847	1.603
MDz[1,1,2]	-1.802	0.5805	0.005676	-2.95	-1.803	-0.6515
MDz[1,1,3]	-0.4878	0.7151	0.004446	-1.892	-0.49	0.9301
MDz[1,1,4]	-1.396	1.245	0.004069	-3.857	-1.395	1.064
MDz[1,1,5]	-0.4198	1.051	0.004483	-2.493	-0.422	1.67
MDz[1,1,6]	-2.875	0.6879	0.003466	-4.236	-2.874	-1.518
MDz[1,1,7]	-3.682	1.022	0.005171	-5.702	-3.684	-1.647
MDz[1,1,8]	-4.076	0.7199	0.005364	-5.516	-4.07	-2.672
MDz[1,2,3]	1.315	0.583	0.001822	0.1687	1.313	2.473
MDz[1,2,4]	0.4069	1.231	0.003639	-2.031	0.4083	2.84
MDz[1,2,5]	1.383	0.9931	0.002836	-0.5771	1.382	3.352
MDz[1,2,6]	-1.073	0.6619	0.002951	-2.388	-1.071	0.2312
MDz[1,2,7]	-1.88	0.9049	0.00188	-3.669	-1.881	-0.08246
MDz[1,2,8]	-2.273	0.479	0.001047	-3.24	-2.268	-1.343
MDz[1,3,4]	-0.9077	1.333	0.003101	-3.556	-0.9041	1.721
MDz[1,3,5]	0.06801	1.127	0.0025	-2.162	0.06875	2.299
MDz[1,3,6]	-2.387	0.8373	0.002216	-4.05	-2.383	-0.7433
MDz[1,3,7]	-3.195	0.8376	0.001359	-4.855	-3.195	-1.534
MDz[1,3,8]	-3.588	0.7473	0.00184	-5.087	-3.581	-2.131
MDz[1,4,5]	0.9757	1.367	0.002466	-1.727	0.9708	3.687
MDz[1,4,6]	-1.48	1.037	0.001704	-3.534	-1.48	0.5715
MDz[1,4,7]	-2.287	1.509	0.003545	-5.268	-2.287	0.7023
MDz[1,4,8]	-2.68	1.314	0.003484	-5.296	-2.674	-0.09592


MDz[1,5,6]	-2.455	0.8902	0.001644	-4.226	-2.453	-0.7074
MDz[1,5,7]	-3.263	1.329	0.002909	-5.891	-3.263	-0.634
MDz[1,5,8]	-3.656	1.095	0.002772	-5.844	-3.648	-1.51
MDz[1,6,7]	-0.8073	1.095	0.002839	-2.965	-0.8093	1.369
MDz[1,6,8]	-1.201	0.8028	0.002779	-2.8	-1.197	0.3744
MDz[1,7,8]	-0.3934	1.02	0.002021	-2.437	-0.3847	1.603
SUCRA[1]	0.009941	0.05011	8.64E-04	0	0	0.1429
SUCRA[2]	0.5161	0.09714	2.98E-04	0.2857	0.5714	0.7143
SUCRA[3]	0.252	0.1112	3.52E-04	0.1429	0.2857	0.4286
SUCRA[4]	0.434	0.1872	4.85E-04	0.1429	0.4286	0.8571
SUCRA[5]	0.2519	0.1343	4.24E-04	0	0.2857	0.5714
SUCRA[6]	0.7364	0.09431	2.47E-04	0.5714	0.7143	1
SUCRA[7]	0.8617	0.1304	2.75E-04	0.5714	0.8571	1
SUCRA[8]	0.938	0.0864	1.90E-04	0.7143	1	1
SUCRAz[1]	0.101	0.1159	6.01E-04	0	0.1429	0.4286
SUCRAz[2]	0.516	0.0974	3.10E-04	0.2857	0.5714	0.7143
SUCRAz[3]	0.2204	0.1383	4.22E-04	0	0.2857	0.4286
SUCRAz[4]	0.4181	0.2104	4.30E-04	0	0.4286	0.8571
SUCRAz[5]	0.2084	0.1717	3.67E-04	0	0.1429	0.5714
SUCRAz[6]	0.7364	0.09425	2.43E-04	0.5714	0.7143	1
SUCRAz[7]	0.8617	0.1307	2.76E-04	0.5714	0.8571	1
SUCRAz[8]	0.938	0.08639	1.90E-04	0.7143	1	1
sd	1.377	0.2482	0.001656	0.9778	1.347	1.947
totresdev	69.08	11.59	0.02489	48.23	68.46	93.51

Gender ratio=(n[female] x 2+ n[male] x1)/n[total]

or: Gender ratio≤1.5 orz: Gender ratio>1.5

4.4 FS-14 physical score of CFS patients

A. network map




B. Contribution plot

"Contribution plot for FS-14 physical score"

		Direct comparisons in the network						
		AvsB	AvsC	AvsE	BvsC	BvsD	BvsE	CvsD
Network meta-analysis estimates	Mixed estimates							
	AvsB	8:1				26.2		65.7
	AvsC		77.1	5:7	1:4		5:7	
	AvsE		1:3	66.9	1:3		6:6	
	BvsC		43.5	21.8	12:9		21.8	
	BvsD	8:1				26.2		65.7
	BvsE		1:9	0.9	1:9		95.3	
CvsD	8:1				26.2		65.7	
Indirect estimates	AvsD	8:1				26.2		65.7
	CvsE	1:9	41.6	2:8	5:6	6:2	26.4	15.5
	EvsD	8:1				26.2		65.7
Entire network		3:6	21.9	1:5	5:5	1:6	16.8	29.1
Included studies		4	1	2	2	1	6	1

A- Acupuncture with moxibustion; B- Acupuncture; C- Moxibustion; E- Western medicine; F- No control

C. Convergence diagram



Potential scale reduction factors:

	Point est.	Upper C.I.
d.2.1	1	1
d.2.3	1	1
d.2.4	1	1
d.2.5	1	1
sd.d	1	1

1- Acupuncture with moxibustion; 2- Acupuncture; 3- Moxibustion; 4- Western medicine;
5- No control

D. Trajectories and density diagram

Results on the Log Odds Ratio scale

Iterations = 10010:60000

Thinning interval = 10

Number of chains = 4

Sample size per chain = 5000

1. Empirical mean and standard deviation for each variable, plus standard error

of the mean:

	Mean	SD	NaiveSE	Time-seriesSE
d.2.1	1.2119	0.4372	0.003092	0.003060
d.2.3	1.0951	0.5808	0.004107	0.004063
d.2.4	-1.0786	0.7334	0.005186	0.005175
d.2.5	-0.8530	0.3808	0.002692	0.002691
sd.d	0.9035	0.2427	0.001716	0.001742


2. Quantiles for each variable:


	2.5%	25%	50%	75%	97.5%
d.2.1	0.34393	0.9367	1.2162	1.4861	2.0766
d.2.3	-0.07591	0.7336	1.1007	1.4569	2.2597
d.2.4	-2.54393	-1.5381	-1.0774	-0.6191	0.3775
d.2.5	-1.60533	-1.0937	-0.8555	-0.6128	-0.0871
sd.d	0.55527	0.7335	0.8639	1.0263	1.5014

3. Model fit (residual deviance):


Dbar: 27.52494 pD: 26.74782 DIC:54.27276

27data points, ratio 0.983, $I^2= 2\%$





E. Forest plot



F. League table

Acupuncture with moxibustion				
3.37 (1.41, 7.98)	Acupuncture			
1.12 (0.3, 4.31)	0.33 (0.1, 1.08)	Moxibustion		
9.87 (1.85, 51.66)	2.95 (0.69, 12.73)	8.84 (2, 37.9)	Western medicine	
7.91 (2.92, 20.94)	2.35 (1.09, 4.98)	7.05 (1.79, 27.04)	0.8 (0.15, 4.06)	No control

G. Inconsistency and Heterogeneity

a. Loops of Statistical Inconsistency:

Loop	IF	self	z_value	p_value	CI_95	Loop_Heterog_tau
------	----	------	---------	---------	-------	------------------

						2
AM-Acu-NC	1.655	0.655	2.526	0.013	(0.37,2.94)	0.341
Acu-Mox-WM	0.897	0.272	3.291	0.001	(0.36,1.43)	0.000
AM-Acu-Mox	0.253	1.313	0.193	0.847	(0.00,2.83)	0.838

b. Side-splitting

Side	Direct		Indirect		Difference		P> z	tau
	Coef.	Std. Err.	Coef.	Std. Err.	Coef.	Std. Err.		
A B	-1.509609	.3989677	-1.890671	.7420173	-1.320542	.8413748	0.117	.7314626
A C	-.7203902	.8712461	.368167	.7723588	-1.088557	1.167275	0.351	.7946764
A E	-1.112339	.4726905	-3.046441	.4700077	1.934102	.6696152	0.004	.5736396
B C	1.220922	.6089278	.7705572	.9953524	.4503651	1.167956	0.700	.8263071
B D	-1.2	.8550631	-.8945828	1.023501	-.3054172	1.333674	0.819	.8322056
B E	-1.181286	.2602647	1.197459	.6590426	-2.378745	.7091628	0.001	.5304401
C D	-2.05	.8432037	-2.355364	1.0333	.3053638	1.33368	0.819	.832206


* All the evidence about these contrasts comes from the trials which directly compare them.

c. Design-by-treatment test

chi2(6) = 24.36


Prob > chi2 = 0.0004

H.Comparison-adjusted funnel plot




I.SUCRA diagram

a. Ranking probability diagram



b. Cumulative probability ranking diagram



AM-Acupuncture with moxibustion; A-Acupuncture; M-Moxibustion; W-Western medicine; NC-No control.

J.Subgroup analysis

a. age

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	-0.5121	1.156	0.0107	-2.811	-0.5133	1.786
MD[1,2]	-1.112	0.5115	0.002848	-2.124	-1.114	-0.08831
MD[1,3]	-0.03747	0.725	0.002725	-1.484	-0.03596	1.399
MD[1,4]	-2.198	0.8973	0.003184	-3.987	-2.199	-0.4069

MD[1,5]	-1.991	0.5532	0.002465	-3.083	-1.995	-0.8842
MD[2,3]	1.075	0.6158	0.001153	-0.1611	1.078	2.292
MD[2,4]	-1.086	0.7757	0.001354	-2.641	-1.085	0.4565
MD[2,5]	-0.8786	0.4048	8.35E-04	-1.679	-0.8794	-0.0702
MD[3,4]	-2.16	0.7736	0.001144	-3.699	-2.162	-0.6067
MD[3,5]	-1.953	0.7191	0.001347	-3.372	-1.958	-0.5096
MD[4,5]	0.207	0.8682	0.001631	-1.514	0.2049	1.95
MDz[1,1,2]	-1.624	1.038	0.008389	-3.682	-1.629	0.4508
MDz[1,1,3]	-0.5496	1.206	0.008954	-2.956	-0.5499	1.855
MDz[1,1,4]	-2.71	1.294	0.008782	-5.286	-2.711	-0.1228
MDz[1,1,5]	-2.503	1.114	0.008906	-4.71	-2.51	-0.2777
MDz[1,2,3]	1.075	0.6158	0.001153	-0.1611	1.078	2.292
MDz[1,2,4]	-1.086	0.7757	0.001354	-2.641	-1.085	0.4565
MDz[1,2,5]	-0.8786	0.4048	8.35E-04	-1.679	-0.8794	-0.0702
MDz[1,3,4]	-2.16	0.7736	0.001144	-3.699	-2.162	-0.6067
MDz[1,3,5]	-1.953	0.7191	0.001347	-3.372	-1.958	-0.5096
MDz[1,4,5]	0.207	0.8682	0.001631	-1.514	0.2049	1.95
SUCRA[1]	0.1272	0.1398	4.94E-04	0	0	0.25
SUCRA[2]	0.5082	0.09711	1.89E-04	0.25	0.5	0.75
SUCRA[3]	0.1436	0.1507	4.10E-04	0	0.25	0.5
SUCRA[4]	0.8783	0.1694	3.15E-04	0.5	1	1
SUCRA[5]	0.8427	0.1339	2.38E-04	0.75	0.75	1
SUCRAz[1]	0.1008	0.1759	0.001199	0	0	0.5
SUCRAz[2]	0.4987	0.1061	3.15E-04	0.25	0.5	0.75
SUCRAz[3]	0.1856	0.1384	6.85E-04	0	0.25	0.5
SUCRAz[4]	0.8758	0.1728	3.53E-04	0.5	1	1
SUCRAz[5]	0.8392	0.1388	3.14E-04	0.5	0.75	1
sd	0.9502	0.2745	0.001115	0.569	0.9007	1.619
totresdev	27.56	7.375	0.0154	15.05	26.9	43.75

or: Average age ≤40 years orz: Average age >40 years

b. course of disease

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	-1.267	13.63	0.3717	-4.171	-1.387	11.28
MD[1,2]	-0.9293	2.732	0.07256	-2.734	-0.9056	0.3072
MD[1,3]	0.1128	2.239	0.05542	-1.866	0.1372	1.762
MD[1,4]	-2.034	2.609	0.0639	-4.421	-2.009	0.01093
MD[1,5]	-1.853	2.163	0.05587	-3.464	-1.838	-0.5558
MD[2,3]	1.042	1.025	0.01722	-0.3378	1.045	2.438
MD[2,4]	-1.104	1.075	0.008847	-2.798	-1.103	0.584
MD[2,5]	-0.924	0.8146	0.01672	-1.823	-0.9319	0.05945
MD[3,4]	-2.146	1.072	0.008572	-3.832	-2.147	-0.46
MD[3,5]	-1.966	0.9496	0.001652	-3.483	-1.976	-0.3849
MD[4,5]	0.1804	1.172	0.008212	-1.67	0.1707	2.081

MDz[1,1,2]	-2.196	10.99	0.2991	-4.773	-2.292	6.751
MDz[1,1,3]	-1.154	11.64	0.3163	-4.157	-1.247	7.771
MDz[1,1,4]	-3.3	11.35	0.3078	-6.525	-3.393	4.958
MDz[1,1,5]	-3.12	11.6	0.3158	-5.886	-3.226	6.272
MDz[1,2,3]	1.042	1.025	0.01722	-0.3378	1.045	2.438
MDz[1,2,4]	-1.104	1.075	0.008847	-2.798	-1.103	0.584
MDz[1,2,5]	-0.924	0.8146	0.01672	-1.823	-0.9319	0.05945
MDz[1,3,4]	-2.146	1.072	0.008572	-3.832	-2.147	-0.46
MDz[1,3,5]	-1.966	0.9496	0.001652	-3.483	-1.976	-0.3849
MDz[1,4,5]	0.1804	1.172	0.008212	-1.67	0.1707	2.081
SUCRA[1]	0.1684	0.1734	0.002909	0	0.25	0.5
SUCRA[2]	0.5006	0.1134	0.001753	0.25	0.5	0.75
SUCRA[3]	0.1228	0.1602	0.001604	0	0	0.5
SUCRA[4]	0.8717	0.1775	0.001673	0.5	1	1
SUCRA[5]	0.8365	0.1459	0.001437	0.5	0.75	1
SUCRAz[1]	0.05416	0.1827	0.004482	0	0	1
SUCRAz[2]	0.5026	0.08937	6.74E-04	0.25	0.5	0.75
SUCRAz[3]	0.2395	0.1162	0.001616	0	0.25	0.5
SUCRAz[4]	0.8704	0.1745	0.001909	0.5	1	1
SUCRAz[5]	0.8334	0.1573	0.002195	0.5	0.75	1
sd	1.007	0.8305	0.02165	0.4864	0.8047	4.89
totresdev	45.13	5433	10.27	15.15	27	43.98

or: Average course of disease ≤ 1 year orz: Average course of disease > 1 year

c. Duration of treatment

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	23.84	135.4	3.698	-113.1	-46.76	239.8
MD[1,2]	-24.72	135.4	3.698	-240.6	45.81	112.2
MD[1,3]	-23.91	135.4	3.698	-239.6	46.54	112.9
MD[1,4]	-25.42	135.4	3.697	-241.1	44.96	111.4
MD[1,5]	-25.55	135.4	3.698	-241.4	44.96	111.3
MD[2,3]	0.8096	0.7615	0.00124	-0.5874	0.8144	2.183
MD[2,4]	-0.7042	0.8794	0.001366	-2.455	-0.7014	1.033
MD[2,5]	-0.8329	0.5423	7.90E-04	-1.889	-0.8318	0.2147
MD[3,4]	-1.514	0.9086	0.00117	-3.252	-1.517	0.2308
MD[3,5]	-1.643	0.941	0.001662	-3.332	-1.647	0.05976
MD[4,5]	-0.1287	1.023	0.00171	-2.142	-0.1306	1.894
MDz[1,1,2]	-0.8751	0.5552	0.001393	-1.9	-0.8762	0.1585
MDz[1,1,3]	-0.06547	0.9131	0.002156	-1.652	-0.06134	1.512
MDz[1,1,4]	-1.579	1.01	0.00226	-3.543	-1.578	0.3872
MDz[1,1,5]	-1.708	0.6195	0.001322	-2.926	-1.709	-0.4852
MDz[1,2,3]	0.8096	0.7615	0.00124	-0.5874	0.8144	2.183
MDz[1,2,4]	-0.7042	0.8794	0.001366	-2.455	-0.7014	1.033
MDz[1,2,5]	-0.8329	0.5423	7.90E-04	-1.889	-0.8318	0.2147

MDz[1,3,4]	-1.514	0.9086	0.00117	-3.252	-1.517	0.2308
MDz[1,3,5]	-1.643	0.941	0.001662	-3.332	-1.647	0.05976
MDz[1,4,5]	-0.1287	1.023	0.00171	-2.142	-0.1306	1.894
SUCRA[1]	0.6666	0.4714	0.01287	0	1	1
SUCRA[2]	0.3664	0.1861	0.003253	0	0.25	0.75
SUCRA[3]	0.1275	0.169	0.003213	0	0	0.5
SUCRA[4]	0.6369	0.2358	0.003185	0.25	0.75	1
SUCRA[5]	0.7026	0.1995	0.003254	0.25	0.75	1
SUCRAz[1]	0.1414	0.1677	3.72E-04	0	0	0.5
SUCRAz[2]	0.5223	0.1545	1.97E-04	0.25	0.5	0.75
SUCRAz[3]	0.1778	0.197	3.52E-04	0	0.25	0.75
SUCRAz[4]	0.7909	0.2333	3.70E-04	0.25	0.75	1
SUCRAz[5]	0.8677	0.1644	2.54E-04	0.5	1	1
sd	1.072	0.3292	8.32E-04	0.631	1.009	1.884
totresdev	48.37	9146	15.38	12.32	23.23	39.18

or: Duration of treatment ≤ 4 weeks or: Duration of treatment > 4 weeks

d. Principle of acupoint selection

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	-0.0897	100	0.1485	-196.4	-0.2775	196
MD[1,2]	-1.211	0.4375	0.001396	-2.078	-1.212	-0.3352
MD[1,3]	-0.1137	0.672	0.001864	-1.457	-0.1112	1.219
MD[1,4]	-2.287	0.8316	0.002187	-3.945	-2.286	-0.627
MD[1,5]	-2.067	0.5	0.001473	-3.056	-2.069	-1.065
MD[2,3]	1.097	0.585	0.001023	-0.07957	1.101	2.259
MD[2,4]	-1.076	0.7356	0.001316	-2.547	-1.074	0.3893
MD[2,5]	-0.8562	0.383	6.26E-04	-1.615	-0.8575	-0.09361
MD[3,4]	-2.173	0.7334	0.001045	-3.632	-2.175	-0.7051
MD[3,5]	-1.953	0.6854	0.001316	-3.31	-1.958	-0.575
MD[4,5]	0.2199	0.8231	0.00156	-1.415	0.2184	1.861
MDz[1,1,2]	-1.3	100	0.1485	-197.6	-1.48	194.8
MDz[1,1,3]	-0.2034	100	0.1485	-196.4	-0.4027	195.9
MDz[1,1,4]	-2.377	100	0.1485	-198.7	-2.586	193.7
MDz[1,1,5]	-2.157	100	0.1485	-198.4	-2.334	193.9
MDz[1,2,3]	1.097	0.585	0.001023	-0.07957	1.101	2.259
MDz[1,2,4]	-1.076	0.7356	0.001316	-2.547	-1.074	0.3893
MDz[1,2,5]	-0.8562	0.383	6.26E-04	-1.615	-0.8575	-0.09361
MDz[1,3,4]	-2.173	0.7334	0.001045	-3.632	-2.175	-0.7051
MDz[1,3,5]	-1.953	0.6854	0.001316	-3.31	-1.958	-0.575
MDz[1,4,5]	0.2199	0.8231	0.00156	-1.415	0.2184	1.861
SUCRA[1]	0.1101	0.1301	3.23E-04	0	0	0.25
SUCRA[2]	0.5108	0.08605	1.29E-04	0.25	0.5	0.75
SUCRA[3]	0.1534	0.1438	3.24E-04	0	0.25	0.5
SUCRA[4]	0.8843	0.162	2.98E-04	0.5	1	1

SUCRA[5]	0.8414	0.131	2.33E-04	0.75	0.75	1
SUCRAz[1]	0.4934	0.498	7.51E-04	0	0	1
SUCRAz[2]	0.3887	0.1504	2.32E-04	0.25	0.5	0.75
SUCRAz[3]	0.1358	0.1375	2.11E-04	0	0.25	0.25
SUCRAz[4]	0.7634	0.201	3.39E-04	0.25	0.75	1
SUCRAz[5]	0.7188	0.1809	3.01E-04	0.5	0.75	1
sd	0.905	0.2472	7.18E-04	0.5527	0.8628	1.509
totresdev	27.5	7.351	0.01557	15.05	26.84	43.71

or: fixed points orz: semi-fixed points

e.gender

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	-10.97	83.5	2.45	-150.5	29.04	97.68
MD[1,2]	9.76	83.5	2.45	-98.62	-30.25	149.3
MD[1,3]	10.86	83.5	2.45	-97.42	-29.13	150.4
MD[1,4]	8.685	83.5	2.45	-99.4	-31.28	148.3
MD[1,5]	8.904	83.5	2.45	-99.38	-31.1	148.5
MD[2,3]	1.097	0.5817	0.001022	-0.07314	1.101	2.249
MD[2,4]	-1.075	0.7336	0.001369	-2.544	-1.073	0.3842
MD[2,5]	-0.8562	0.3819	6.72E-04	-1.615	-0.8566	-0.09591
MD[3,4]	-2.172	0.7305	0.001041	-3.631	-2.173	-0.7083
MD[3,5]	-1.953	0.6831	0.001335	-3.303	-1.958	-0.5796
MD[4,5]	0.219	0.8206	0.001642	-1.414	0.2166	1.865
MDz[1,1,2]	-1.212	0.4363	0.001331	-2.079	-1.213	-0.3396
MDz[1,1,3]	-0.1146	0.6682	0.001805	-1.452	-0.1136	1.211
MDz[1,1,4]	-2.287	0.8291	0.002152	-3.941	-2.287	-0.6323
MDz[1,1,5]	-2.068	0.5	0.001428	-3.058	-2.07	-1.069
MDz[1,2,3]	1.097	0.5817	0.001022	-0.07314	1.101	2.249
MDz[1,2,4]	-1.075	0.7336	0.001369	-2.544	-1.073	0.3842
MDz[1,2,5]	-0.8562	0.3819	6.72E-04	-1.615	-0.8566	-0.09591
MDz[1,3,4]	-2.172	0.7305	0.001041	-3.631	-2.173	-0.7083
MDz[1,3,5]	-1.953	0.6831	0.001335	-3.303	-1.958	-0.5796
MDz[1,4,5]	0.219	0.8206	0.001642	-1.414	0.2166	1.865
SUCRA[1]	0.3478	0.4723	0.01381	0	0	1
SUCRA[2]	0.4251	0.1456	0.003478	0.25	0.5	0.75
SUCRA[3]	0.1706	0.1327	0.00348	0	0.25	0.25
SUCRA[4]	0.8006	0.1968	0.003457	0.5	0.75	1
SUCRA[5]	0.7558	0.1768	0.003476	0.5	0.75	1
SUCRAz[1]	0.1097	0.13	3.13E-04	0	0	0.25
SUCRAz[2]	0.5109	0.08565	1.34E-04	0.25	0.5	0.75
SUCRAz[3]	0.1535	0.1434	3.16E-04	0	0.25	0.5
SUCRAz[4]	0.8846	0.1616	3.05E-04	0.5	1	1
SUCRAz[5]	0.8414	0.131	2.43E-04	0.75	0.75	1
sd	0.9028	0.2456	7.24E-04	0.5521	0.8609	1.499


totresdev 27.5 7.353 0.01491 15.03 26.86 43.71

Gender ratio=(n[female] x 2+ n[male] x1)/n[total]

or: Gender ratio≤1.5 orz: Gender ratio>1.5


4.5 FS-14 mental score of CFS patients

A.network map




B.Contribution plot

"Contribution plot for FS-14 mental score"



A- Acupuncture with moxibustion; B- Acupuncture; C- Moxibustion; E- Western medicine; F- No control

C. Convergence diagram



Potential scale reduction factors:

	Point est.	Upper C.I.
d.2.1	1	1
d.2.3	1	1
d.2.4	1	1
d.2.5	1	1
sd.d	1	1

1- Acupuncture with moxibustion; 2- Acupuncture; 3- Moxibustion; 4- Western medicine; 5- No control

D.Trajectories and density diagram

Results on the Log Odds Ratio scale

Iterations = 10010:60000

Thinning interval = 10

Number of chains = 4

Sample size per chain = 5000

1. Empirical mean and standard deviation for each variable, plus standard error of the mean:

	Mean	SD	NaiveSE	Time-seriesSE
d.2.1	0.8415	0.4661	0.003296	0.003329
d.2.3	0.8173	0.6300	0.004455	0.004384
d.2.4	-0.7017	0.7871	0.005566	0.005566

d.2.5	-0.9343	0.4096	0.002896	0.002897
sd.d	0.9828	0.2590	0.001831	0.001879


2. Quantiles for each variable:


	2.5%	25%	50%	75%	97.5%
d.2.1	-0.08802	0.5496	0.8435	1.1323	1.7593
d.2.3	-0.45380	0.4254	0.8198	1.2072	2.0794
d.2.4	-2.30161	-1.1918	-0.6961	-0.2080	0.8723
d.2.5	-1.75546	-1.1912	-0.9332	-0.6772	-0.1181
sd.d	0.60651	0.8016	0.9373	1.1131	1.6296

3. Model fit (residual deviance):


Dbar: 27.70335 pD: 27.10428 DIC:54.80762

28 data points, ratio 0.9894, I²= 3%





E. Forest plot



F. League table

Acupuncture with moxibustion					
2.32 (0.92, 5.81)	Acupuncture				
1.03 (0.25, 4.26)	0.44 (0.13, 1.57)	Moxibustion			
4.67 (0.8, 8.54)	2.01 (0.42, 3.6)	4.6 (0.97, 8.23)	Western		

27.85)	9.99)	21.55)	medicine	
5.88 (2.03, 17.24)	2.54 (1.13, 5.79)	5.77 (1.32, 25.25)	1.26 (0.21, 7.36)	No control

G. Inconsistency and Heterogeneity

a. Loops of Statistical Inconsistency:

Loop	IF	self	z_value	p_value	CI_95	Loop_Heterog_tau2
AM-Acu-WM	1.528	0.889	1.718	0.886	(0.00,3.27)	0.761
AM-Acu-Mox	0.745	1.657	0.450	0.653	(0.00,3.99)	1.403
Acu-Mo-NC	0.335	0.228	1.466	0.143	(0.00,0.78)	0.000

b. Side-splitting

Side	Direct		Indirect		Difference		P> z	tau
	Coef.	Std. Err.	Coef.	Std. Err.	Coef.	Std. Err.		
A B	-1.053246	.4494383	-.104083	.8483489	-.949163	.9617843	0.324	.8607026
A C	-.9358651	.9060654	.6794506	.8012152	-1.615316	1.20907	0.182	.8361518
A E	-.8042756	.4846723	-2.839311	.5019041	2.035035	.6980684	0.004	.641162
B C	.8918981	.6663418	.5902405	1.076576	.3016576	1.264029	0.811	.9079177
B D	-.5600001	.9198388	-.9203103	1.115159	.3603102	1.445574	0.803	.9093625
B E	-1.246478	.2995874	1.090854	.7647471	-2.337332	.8226802	0.004	.6541502
C D	-1.66	.9189004	-1.29962	1.115943	-.3603803	1.445582	0.803	.909363


* All the evidence about these contrasts comes from the trials which directly compare them.

c. Design-by-treatment test

chi2(6)=10.15


Prob>chi2=0.1187

H. Comparison-adjusted funnel plot




I.SUCRA diagram

a. Ranking probability diagram



b. Cumulative probability ranking diagram



J.Subgroup analysis

a. age

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	-0.1317	1.224	0.01792	-2.544	-0.1394	2.333
MD[1,2]	-0.8154	0.5489	0.004006	-1.91	-0.8162	0.2829
MD[1,3]	-0.01827	0.7899	0.003541	-1.603	-0.01347	1.547
MD[1,4]	-1.526	0.9774	0.004062	-3.476	-1.523	0.426
MD[1,5]	-1.759	0.5926	0.003244	-2.942	-1.76	-0.5732
MD[2,3]	0.7972	0.6787	0.001381	-0.5689	0.8024	2.138
MD[2,4]	-0.7102	0.8508	0.001532	-2.415	-0.7084	0.9832
MD[2,5]	-0.944	0.4381	0.001072	-1.818	-0.9429	-0.07145
MD[3,4]	-1.507	0.85	0.001205	-3.199	-1.51	0.1972
MD[3,5]	-1.741	0.7871	0.001389	-3.299	-1.745	-0.159
MD[4,5]	-0.2337	0.9484	0.00177	-2.124	-0.2349	1.664
MDz[1,1,2]	-0.9471	1.1	0.01426	-3.125	-0.953	1.276
MDz[1,1,3]	-0.1499	1.289	0.0151	-2.712	-0.1503	2.437
MDz[1,1,4]	-1.657	1.388	0.01476	-4.41	-1.66	1.123
MDz[1,1,5]	-1.891	1.181	0.01512	-4.225	-1.897	0.4908
MDz[1,2,3]	0.7972	0.6787	0.001381	-0.5689	0.8024	2.138
MDz[1,2,4]	-0.7102	0.8508	0.001532	-2.415	-0.7084	0.9832
MDz[1,2,5]	-0.944	0.4381	0.001072	-1.818	-0.9429	-0.07145
MDz[1,3,4]	-1.507	0.85	0.001205	-3.199	-1.51	0.1972
MDz[1,3,5]	-1.741	0.7871	0.001389	-3.299	-1.745	-0.159
MDz[1,4,5]	-0.2337	0.9484	0.00177	-2.124	-0.2349	1.664
SUCRA[1]	0.1539	0.1758	8.55E-04	0	0.25	0.5

SUCRA[2]	0.5074	0.1517	4.28E-04	0.25	0.5	0.75
SUCRA[3]	0.1679	0.1915	5.00E-04	0	0.25	0.75
SUCRA[4]	0.7789	0.2294	4.58E-04	0.25	0.75	1
SUCRA[5]	0.892	0.1422	2.67E-04	0.5	1	1
SUCRAz[1]	0.1966	0.2682	0.002994	0	0	1
SUCRAz[2]	0.4787	0.1652	8.66E-04	0.25	0.5	0.75
SUCRAz[3]	0.1787	0.1846	0.001216	0	0.25	0.5
SUCRAz[4]	0.7663	0.2374	7.09E-04	0.25	0.75	1
SUCRAz[5]	0.8797	0.1565	6.67E-04	0.5	1	1
sd	1.05	0.296	0.0015	0.6381	0.9962	1.775
totresdev	27.74	7.414	0.01515	15.14	27.09	44.05

or: Average age ≤40 years orz: Average age >40 years

b. course of disease

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	-1.863	0.9779	0.01834	-3.808	-1.871	0.1089
MD[1,2]	-0.4551	0.452	0.004129	-1.358	-0.4549	0.4471
MD[1,3]	0.2849	0.6505	0.003557	-1.038	0.2923	1.567
MD[1,4]	-1.195	0.7957	0.004089	-2.8	-1.191	0.3793
MD[1,5]	-1.487	0.4864	0.003293	-2.459	-1.487	-0.5193
MD[2,3]	0.7399	0.5526	0.001296	-0.3797	0.7468	1.825
MD[2,4]	-0.7399	0.6871	0.001242	-2.122	-0.7359	0.6262
MD[2,5]	-1.032	0.3613	0.001088	-1.751	-1.032	-0.31
MD[3,4]	-1.48	0.6867	0.001061	-2.848	-1.483	-0.09809
MD[3,5]	-1.772	0.644	0.00126	-3.035	-1.78	-0.4649
MD[4,5]	-0.2923	0.7691	0.001539	-1.822	-0.297	1.256
MDz[1,1,2]	-2.318	0.8734	0.01448	-4.059	-2.321	-0.5601
MDz[1,1,3]	-1.578	1.033	0.01536	-3.655	-1.572	0.4736
MDz[1,1,4]	-3.058	1.11	0.01491	-5.279	-3.054	-0.8391
MDz[1,1,5]	-3.351	0.9427	0.01539	-5.227	-3.354	-1.45
MDz[1,2,3]	0.7399	0.5526	0.001296	-0.3797	0.7468	1.825
MDz[1,2,4]	-0.7399	0.6871	0.001242	-2.122	-0.7359	0.6262
MDz[1,2,5]	-1.032	0.3613	0.001088	-1.751	-1.032	-0.31
MDz[1,3,4]	-1.48	0.6867	0.001061	-2.848	-1.483	-0.09809
MDz[1,3,5]	-1.772	0.644	0.00126	-3.035	-1.78	-0.4649
MDz[1,4,5]	-0.2923	0.7691	0.001539	-1.822	-0.297	1.256
SUCRA[1]	0.2233	0.1848	0.001171	0	0.25	0.75
SUCRA[2]	0.4761	0.1475	6.58E-04	0.25	0.5	0.75
SUCRA[3]	0.1056	0.1695	5.55E-04	0	0	0.5
SUCRA[4]	0.7828	0.2042	4.31E-04	0.25	0.75	1
SUCRA[5]	0.9122	0.1266	2.66E-04	0.75	1	1
SUCRAz[1]	0.01865	0.08393	0.001066	0	0	0.25
SUCRAz[2]	0.5095	0.1155	2.99E-04	0.25	0.5	0.75
SUCRAz[3]	0.263	0.1096	6.07E-04	0	0.25	0.5

SUCRAz[4]	0.7963	0.1756	3.53E-04	0.5	0.75	1
SUCRAz[5]	0.9126	0.1257	3.12E-04	0.75	1	1
sd	0.8429	0.2487	0.001563	0.4913	0.7997	1.449
totresdev	27.87	7.454	0.01486	15.22	27.21	44.24

or: Average course of disease \leq 1 year orz: Average course of disease $>$ 1 year

c. Duration of treatment

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	19.16	107.6	3.158	-75.51	-47.74	203.1
MD[1,2]	-20.39	107.6	3.158	-204.4	46.49	74.31
MD[1,3]	-19.29	107.6	3.157	-203.3	47.59	75.44
MD[1,4]	-21.46	107.6	3.157	-205.5	45.42	73.31
MD[1,5]	-21.18	107.6	3.158	-205.2	45.7	73.55
MD[2,3]	1.096	0.6408	0.001105	-0.1988	1.102	2.36
MD[2,4]	-1.076	0.8078	0.001435	-2.698	-1.073	0.5239
MD[2,5]	-0.7915	0.4929	7.99E-04	-1.78	-0.7902	0.1894
MD[3,4]	-2.173	0.8065	0.001142	-3.777	-2.175	-0.557
MD[3,5]	-1.888	0.7876	0.001474	-3.446	-1.893	-0.3067
MD[4,5]	0.2848	0.9374	0.001791	-1.579	0.2809	2.166
MDz[1,1,2]	-1.226	0.4847	0.001387	-2.182	-1.228	-0.2482
MDz[1,1,3]	-0.1294	0.7351	0.001949	-1.601	-0.1272	1.33
MDz[1,1,4]	-2.302	0.9132	0.002284	-4.125	-2.301	-0.4835
MDz[1,1,5]	-2.017	0.5768	0.00145	-3.167	-2.019	-0.8612
MDz[1,2,3]	1.096	0.6408	0.001105	-0.1988	1.102	2.36
MDz[1,2,4]	-1.076	0.8078	0.001435	-2.698	-1.073	0.5239
MDz[1,2,5]	-0.7915	0.4929	7.99E-04	-1.78	-0.7902	0.1894
MDz[1,3,4]	-2.173	0.8065	0.001142	-3.777	-2.175	-0.557
MDz[1,3,5]	-1.888	0.7876	0.001474	-3.446	-1.893	-0.3067
MDz[1,4,5]	0.2848	0.9374	0.001791	-1.579	0.2809	2.166
SUCRA[1]	0.6667	0.4714	0.01383	0	1	1
SUCRA[2]	0.3551	0.1569	0.003476	0	0.25	0.75
SUCRA[3]	0.09918	0.1386	0.003453	0	0	0.25
SUCRA[4]	0.7194	0.2011	0.00343	0.25	0.75	1
SUCRA[5]	0.6596	0.1883	0.0035	0.25	0.75	1
SUCRAz[1]	0.1114	0.1347	3.28E-04	0	0	0.25
SUCRAz[2]	0.5193	0.1066	1.63E-04	0.25	0.5	0.75
SUCRAz[3]	0.1598	0.1539	3.38E-04	0	0.25	0.5
SUCRAz[4]	0.8837	0.1721	3.22E-04	0.5	1	1
SUCRAz[5]	0.8258	0.1474	2.68E-04	0.5	0.75	1
sd	0.9874	0.3071	8.66E-04	0.5731	0.9284	1.748
totresdev	23.73	6.837	0.01386	12.29	23.08	38.85

or: Duration of treatment \leq 4 weeks orz: Duration of treatment $>$ 4 weeks

d. Principle of acupoint selection

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	-0.01789	100	0.1247	-195.9	-0.252	196.3
MD[1,2]	-0.8414	0.4912	0.001267	-1.766	-0.8433	0.09157
MD[1,3]	-0.03355	0.7493	0.001698	-1.482	-0.03107	1.401
MD[1,4]	-1.548	0.9	0.001909	-3.335	-1.547	0.2374
MD[1,5]	-1.779	0.5469	0.001346	-2.835	-1.78	-0.7163
MD[2,3]	0.8079	0.6411	9.84E-04	-0.468	0.8124	2.058
MD[2,4]	-0.7062	0.8117	0.001242	-2.299	-0.7025	0.8748
MD[2,5]	-0.9373	0.4346	6.59E-04	-1.756	-0.9361	-0.1236
MD[3,4]	-1.514	0.8133	0.001044	-3.093	-1.516	0.07922
MD[3,5]	-1.745	0.7537	0.00125	-3.207	-1.749	-0.2612
MD[4,5]	-0.2311	0.8982	0.001429	-1.993	-0.2338	1.546
MDz[1,1,2]	-0.8593	100	0.1248	-196.7	-1.09	195.5
MDz[1,1,3]	-0.05144	100	0.1248	-195.9	-0.283	196.4
MDz[1,1,4]	-1.565	100	0.1248	-197.4	-1.78	194.8
MDz[1,1,5]	-1.797	100	0.1248	-197.7	-2.007	194.6
MDz[1,2,3]	0.8079	0.6411	9.84E-04	-0.468	0.8124	2.058
MDz[1,2,4]	-0.7062	0.8117	0.001242	-2.299	-0.7025	0.8748
MDz[1,2,5]	-0.9373	0.4346	6.59E-04	-1.756	-0.9361	-0.1236
MDz[1,3,4]	-1.514	0.8133	0.001044	-3.093	-1.516	0.07922
MDz[1,3,5]	-1.745	0.7537	0.00125	-3.207	-1.749	-0.2612
MDz[1,4,5]	-0.2311	0.8982	0.001429	-1.993	-0.2338	1.546
SUCRA[1]	0.14	0.1591	3.46E-04	0	0	0.5
SUCRA[2]	0.514	0.1385	1.98E-04	0.25	0.5	0.75
SUCRA[3]	0.1637	0.182	3.19E-04	0	0.25	0.5
SUCRA[4]	0.786	0.2169	3.28E-04	0.25	0.75	1
SUCRA[5]	0.8962	0.1367	2.06E-04	0.75	1	1
SUCRAz[1]	0.495	0.4984	6.17E-04	0	0	1
SUCRAz[2]	0.3991	0.179	2.35E-04	0	0.5	0.75
SUCRAz[3]	0.1593	0.1621	2.24E-04	0	0.25	0.5
SUCRAz[4]	0.673	0.2307	3.27E-04	0.25	0.75	1
SUCRAz[5]	0.7737	0.1844	2.50E-04	0.5	0.75	1
sd	0.9875	0.2659	6.42E-04	0.6127	0.9412	1.633
totresdev	45.56	5899	10.42	15.15	27.06	44.02

or: fixed points orz: semi-fixed points

e.gender

	mean	sd	MC_error	val2.5pc	median	val97.5pc
B	3.133	103.7	3.042	-155.8	40.01	116.1
MD[1,2]	-3.975	103.7	3.042	-117	-40.89	154.9
MD[1,3]	-3.169	103.7	3.042	-116.2	-40.15	155.8
MD[1,4]	-4.68	103.7	3.042	-117.8	-41.71	154.3
MD[1,5]	-4.912	103.7	3.042	-118	-41.83	154
MD[2,3]	0.8066	0.6342	0.001117	-0.4649	0.8106	2.059

MD[2,4]	-0.7052	0.7948	0.001426	-2.293	-0.7031	0.8734
MD[2,5]	-0.9365	0.4086	6.55E-04	-1.751	-0.9365	-0.1248
MD[3,4]	-1.512	0.795	0.001084	-3.091	-1.513	0.07633
MD[3,5]	-1.743	0.7392	0.001394	-3.199	-1.749	-0.262
MD[4,5]	-0.2313	0.8877	0.001684	-1.995	-0.2328	1.546
MDz[1,1,2]	-0.8427	0.4645	0.001383	-1.764	-0.8443	0.08812
MDz[1,1,3]	-0.03602	0.7226	0.001892	-1.48	-0.03268	1.396
MDz[1,1,4]	-1.548	0.8951	0.002237	-3.337	-1.545	0.2364
MDz[1,1,5]	-1.779	0.529	0.001442	-2.83	-1.78	-0.7242
MDz[1,2,3]	0.8066	0.6342	0.001117	-0.4649	0.8106	2.059
MDz[1,2,4]	-0.7052	0.7948	0.001426	-2.293	-0.7031	0.8734
MDz[1,2,5]	-0.9365	0.4086	6.55E-04	-1.751	-0.9365	-0.1248
MDz[1,3,4]	-1.512	0.795	0.001084	-3.091	-1.513	0.07633
MDz[1,3,5]	-1.743	0.7392	0.001394	-3.199	-1.749	-0.262
MDz[1,4,5]	-0.2313	0.8877	0.001684	-1.995	-0.2328	1.546
SUCRA[1]	0.3333	0.4714	0.01383	0	0	1
SUCRA[2]	0.4396	0.1744	0.003484	0	0.5	0.75
SUCRA[3]	0.2007	0.1565	0.003454	0	0.25	0.5
SUCRA[4]	0.713	0.2259	0.003448	0.25	0.75	1
SUCRA[5]	0.8133	0.1797	0.003482	0.5	0.75	1
SUCRAz[1]	0.1395	0.1589	4.06E-04	0	0	0.5
SUCRAz[2]	0.514	0.138	2.29E-04	0.25	0.5	0.75
SUCRAz[3]	0.164	0.1823	3.78E-04	0	0.25	0.5
SUCRAz[4]	0.7863	0.2166	4.00E-04	0.25	0.75	1
SUCRAz[5]	0.8961	0.1365	2.47E-04	0.75	1	1
sd	0.9868	0.2642	7.20E-04	0.6137	0.9409	1.629
totresdev	27.71	7.4	0.01479	15.19	27.05	44.04

Gender ratio=(n[female] x 2+ n[male] x1)/n[total]

or: Gender ratio≤1.5 orz: Gender ratio>1.5

5 GRADE for the primary outcomes


5.1 Overall response rate

5.1.1 Contribution of low or moderate RoB comparisons to each network estimate

Based on the assessment of RoB for each comparison and the contribution matrix detailing contribution of each direct comparison to all network estimates, the following bar graphs show the percentage of low or moderate RoB contributions for each network estimate.

Each bar corresponds to a NMA relative treatment effect and shows how much

information comes from comparisons at low risk of bias [green] or moderate risk of bias [yellow].



6	P1	P2	P3	P4	P5	P6	P7	P8	P9	P10	P11	P12	P13	P14	P15
AvsB	56.2	7.3	12.1	8.9	0.7	8.4	1.5	0.0	0.4	0.8	0.3	0.6	0.6	1.0	1.2
AvsC	33.8	6.4	8.3	30.9	0.9	0.2	1.8	0.0	3.2	3.1	4.9	1.1	1.1	2.3	2.0
AvsF	30.6	4.6	11.9	5.5	1.2	21.1	2.7	0.0	2.7	3.9	3.5	2.2	2.2	3.9	4.0
BvsC	3.6	2.7	0.9	56.0	2.0	8.5	4.2	0.0	4.5	4.0	7.2	1.1	1.1	2.5	1.9
BvsE	3.0	0.9	2.1	22.3	8.6	13.9	2.9	0.0	23.2	0.6	0.7	0.8	0.8	18.9	1.4
BvsF	5.7	0.0	5.7	14.3	2.1	34.3	4.7	0.0	3.8	5.7	4.8	3.4	3.4	5.9	6.1
BvsG	2.8	0.8	2.1	20.1	1.2	13.4	13.9	0.0	0.0	0.7	20.1	6.2	6.2	1.2	11.2
BvsH	0.0	0.0	0.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CvsE	0.6	1.1	1.7	17.5	8.0	8.9	0.0	0.0	28.8	3.7	4.6	1.6	1.7	18.9	3.0
CvsF	2.3	1.8	4.0	26.0	0.4	22.3	1.0	0.0	6.2	7.3	8.8	3.5	3.5	6.6	6.3
CvsG	0.4	1.2	1.5	19.5	0.2	7.8	11.5	0.0	3.3	3.6	26.2	5.7	5.7	3.1	10.4
DvsF	0.8	0.3	1.0	3.1	0.2	5.9	3.8	0.0	1.2	1.6	6.1	52.2	16.2	1.4	6.3
DvsG	1.3	0.5	1.7	5.2	0.3	10.0	6.4	0.0	2.1	2.6	10.4	27.3	19.2	2.4	10.6
EvsF	1.8	0.8	2.6	10.6	7.0	14.8	1.1	0.0	20.3	4.2	4.8	2.1	2.1	24.2	3.7
FvsG	1.9	0.7	2.7	7.9	0.5	15.3	9.8	0.0	3.2	4.0	15.9	9.0	9.0	3.7	16.2
AvsD	22.1	3.4	7.9	5.4	0.7	12.1	3.8	0.0	1.3	2.0	5.5	23.9	9.5	2.1	0.2
AvsE	26.7	4.4	7.9	12.6	6.3	6.4	1.4	0.0	17.6	0.0	0.7	0.3	0.3	15.0	0.5
AvsG	26.6	4.3	7.7	10.6	0.6	5.8	9.7	0.0	0.2	0.1	15.0	5.0	5.0	0.4	9.0
AvsH	32.0	4.2	6.9	5.0	0.4	4.8	0.8	43.1	0.2	0.5	0.2	0.4	0.4	0.6	0.7
BvsD	3.3	0.2	3.2	11.4	1.3	19.4	5.4	0.0	1.8	2.9	6.9	28.9	11.9	3.1	0.4
CvsD	1.3	1.2	2.4	17.7	0.2	13.4	2.8	0.0	3.9	4.6	9.9	25.8	11.4	4.1	1.3
CvsH	2.1	1.5	0.5	32.1	1.1	4.9	2.4	42.6	2.6	2.3	4.1	0.6	0.6	1.4	1.1
DvsE	0.8	0.4	1.3	5.8	5.0	7.2	2.7	0.0	14.9	2.1	6.6	26.1	10.0	16.2	0.7
DvsH	2.4	0.1	2.2	8.1	0.9	13.8	3.8	29.0	1.3	2.0	4.9	20.5	8.5	2.2	0.3
EvsG	0.2	0.1	0.1	2.2	6.6	0.6	9.7	0.0	20.7	0.1	18.3	6.2	6.2	17.9	11.1

EvsH	2.0	0.6	1.4	14.8	5.7	9.2	1.9	33.6	15.4	0.4	0.4	0.5	0.5	12.5	0.9
FvsH	3.5	0.0	3.5	8.9	1.3	21.3	2.9	37.9	2.4	3.5	3.0	2.1	2.1	3.7	3.8
GvsH	1.9	0.5	1.4	13.3	0.8	8.9	9.2	34.0	0.0	0.5	13.3	4.1	4.1	0.8	7.4

Compaison	AvsB	AvsC	AvsF	BvsC	BvsE	BvsF	BvsG	BvsH	CvsE
Moderate percent	2.8%	9%	10.1%	13.9%	22.5%	15.4%	35.2%	0%	23.5%
CvsF	CvsG	DvsF	DvsG	EvsF	FvsG	AvsD	AvsE	AvsG	AvsH
16.4%	40.8%	11.3%	19.2%	30.1%	29.4%	11.4%	17.1%	25.1%	1.6%
BvsD	CvsD	CvsH	DvsE	DvsH	EvsG	EvsH	FvsH	GvsH	Entire network
15.4%	16.8%	7.9%	25.5%	10.9%	45.9%	14.8%	9.6%	23.3%	18.2

5.1.2 Table of reasons for downgrading

Based on all the above information, we GRADEd each network estimate according to the following criteria.

- (1) Study limitations: We downgraded by one level when the contributions from low RoB comparisons were less than 30% and contributions from moderate RoB comparisons were 70% or greater.
- (2) Imprecision: We considered a clinically meaningful threshold for OR to be 0.80 or 1.25 and downgraded the estimate if the OR point estimate is 1 or more and the lower limit of its CrI is below 0.80; or if the OR point estimate is less than 1 and the upper limit of its CrI is above 1.25.
- (3) Inconsistency: We rated two concepts, heterogeneity and incoherence (inconsistency), in this domain.
For heterogeneity, we looked at the common tau and found that it is low compared to the expected value as reported in the literature (Turner RM et al (2012) Int J Epidemiol, 41, 818-827) , so we did not downgrade any network estimate for heterogeneity. For inconsistency, we looked at the results of side splitting and we downgraded the comparisons with important inconsistency ($p < 0.05$), where we have not downgraded for imprecision (we did not downgrade the same network estimate for both imprecision and inconsistency).
- (4) Indirectness: We have assured transitivity in our network by limiting the included studies to chronic fatigue syndrome with the diagnostic criteria of "1994 CDC" .We further ran various subgroup analysis, and assured that they did not violate transitivity of the network.
- (5) Publication bias: The comparison-adjusted funnel plot did not suggest obvious publication bias. However, we cannot completely rule out the possibility that some studies are still missing. Considering that the field of CFS trials in the past has been prone to publication bias, the review team decided by default to downgrade all the included studies for potential publication bias by one level.

	Study limitations	Imprecision	Inconsistency	Indirectness	Publication bias	GRADE
AvsB	No	No	No	No	Downgrade	MODERATE

	downgrade	downgrade	downgrade	downgrade		
AvsC	No downgrade	Downgrade Because point estimate >1.0 but lower limit<0.80	No downgrade	No downgrade	Downgrade	LOW
AvsF	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
BvsC	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
BvsE	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
BvsF	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
BvsG	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
BvsH	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
CvsE	No downgrade	Downgrade Because point estimate >1.0 but lower limit<0.80	Downgrade because sidesplitting p=0.014	No downgrade	Downgrade	VERY LOW
CvsF	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
CvsG	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
DvsF	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
DvsG	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
EvsF	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
FvsG	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE


A , acupuncture with moxibustion ; B , acupuncture ; C , moxibustion ; D , acupuncture with THM ; E , moxibustion with THM ; F , traditional chinses herbal medicine(THM); G, western medicine; H, no control group.

5.2 FS-14 total score of CFS patients

5.2.1 Contribution of low or moderate RoB comparisons to each network estimate

Based on the assessment of RoB for each comparison and the contribution matrix detailing contribution of each direct comparison to all network estimates, the following bar graphs show the percentage of low or moderate RoB contributions for each network estimate.

Each bar corresponds to a NMA relative treatment effect and shows how much information comes from comparisons at low risk of bias [green] or moderate risk of bias [yellow].



6	P1	P2	P3	P4	P5	P6	P7	P8	P9	P10	P11	P12
AvsB	11.5	18.6	5.4	13.8	8.1	2.5	2.9	10.5	13.8	10.5	0.0	2.5
AvsC	7.5	34.9	3.5	9.0	8.6	1.6	1.9	11.3	9.0	11.3	0.0	1.6
AvsF	0.5	0.7	94.0	0.6	0.3	0.8	0.9	0.4	0.6	0.4	0.0	0.8
AvsH	7.8	12.6	3.6	27.0	5.5	1.7	1.9	7.1	24.0	7.1	0.0	1.7
BvsC	5.2	13.9	2.4	6.3	17.3	1.1	1.3	22.5	6.3	22.5	0.0	1.1
BvsE	3.8	6.1	14.4	4.5	2.6	40.5	1.1	3.5	4.5	3.4	0.0	15.5
BvsF	8.2	13.3	31.3	9.9	5.8	2.1	2.4	7.5	9.9	7.5	0.0	2.1
BvsG	1.8	4.7	0.8	2.1	5.8	0.4	0.4	70.9	2.1	10.6	0.0	0.4
BvsH	5.4	8.7	2.5	16.5	3.8	1.2	1.3	4.9	49.7	4.9	0.0	1.2
CvsG	4.2	11.2	2.0	5.1	13.9	0.9	1.0	25.1	5.1	30.6	0.0	0.9
DvsF	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	99.9	0.0
EvsF	5.6	9.0	21.4	6.7	3.9	23.0	1.7	5.1	6.7	5.1	0.0	11.7
AvsD	0.2	0.4	48.0	0.3	0.2	0.4	0.5	0.2	0.3	0.2	48.9	0.4
AvsE	6.3	10.1	13.7	7.5	4.4	25.3	1.4	5.7	7.5	5.7	0.0	12.3
AvsG	8.5	17.5	4.0	10.2	3.7	1.8	2.1	26.4	10.2	13.8	0.0	1.8
BvsD	6.2	9.8	23.1	7.3	4.2	1.6	1.8	5.5	7.3	5.5	26.4	1.6
CvsD	3.6	17.0	24.8	4.3	4.4	1.0	1.2	5.7	4.3	5.7	27.1	1.2
CvsE	1.1	13.3	10.9	1.3	9.9	25.4	0.2	12.9	1.3	12.9	0.0	10.8

CvsF	4.9	23.3	34.1	5.9	6.0	1.4	1.6	7.8	5.9	7.8	0.0	1.4
CvsH	0.7	16.4	0.3	15.4	11.1	0.1	0.2	14.5	26.6	14.5	0.0	0.1
DvsE	4.2	6.7	15.9	5.0	2.9	17.1	1.2	3.8	5.0	3.8	25.8	8.7
DvsG	4.9	10.0	20.7	5.8	2.1	1.3	1.5	15.5	5.8	7.9	23.4	1.3
DvsH	3.9	6.3	24.0	13.8	2.7	1.1	1.3	3.6	12.5	3.6	26.3	1.1
EvsG	1.7	6.3	10.2	2.1	0.9	27.3	0.6	30.8	2.1	7.3	0.0	10.7
EvsH	0.6	0.6	12.4	14.0	0.4	29.8	0.0	0.5	28.3	0.5	0.0	12.4
FvsG	6.3	13.0	27.0	7.6	2.7	1.7	1.9	20.2	7.6	10.3	0.0	1.7
FvsH	5.3	8.5	32.5	18.7	3.7	1.5	1.7	4.8	17.0	4.8	0.0	1.5
GvsH	2.5	8.1	1.2	11.8	0.6	0.6	0.6	34.2	31.1	8.7	0.0	0.6

Compaison	AvsB	AvsC	AvsF	AvsH	BvsC	BvsE	BvsF	BvsG	BvsH
Moderate percent	23.5 %	24.2%	1.6%	15.9%	46.1%	22.4%	17.1%	81.9%	11%
CvsG	DvsF	EvsF	AvsD	AvsE	AvsG	BvsD	CvsD	CvsE	CvsF
56.6%	0.0%	21.9%	0.8%	23.7%	42%	12.6%	12.6%	36.6%	17%
CvsH	DvsE	DvsG	DvsH	EvsG	EvsH	FvsG	FvsH	GvsH	Entire network
29.1%	16.3%	24.7%	8.3%	48.8%	13.4%	32.2%	11.1%	43.5%	23.8%

5.2.2 Table of reasons for downgrading

Based on all the above information, we GRADEd each network estimate according to the following criteria.

- (1) Study limitations: We downgraded by one level when the contributions from low RoB comparisons were less than 30% and contributions from moderate RoB comparisons were 70% or greater.
- (2) Imprecision: We considered a clinically meaningful threshold for OR to be 0.80 or 1.25 and downgraded the estimate if the OR point estimate is 1 or more and the lower limit of its CrI is below 0.80; or if the OR point estimate is less than 1 and the upper limit of its CrI is above 1.25.
- (3) Inconsistency: We rated two concepts, heterogeneity and incoherence (inconsistency), in this domain.
For heterogeneity, we looked at the common tau and found that it is low compared to the expected value as reported in the literature (Turner RM et al (2012) Int J Epidemiol, 41, 818-827) , so we did not downgrade any network estimate for heterogeneity. For inconsistency, we looked at the results of side splitting and we downgraded the comparisons with important inconsistency ($p < 0.05$), where we have not downgraded for imprecision (we did not downgrade the same network estimate for both imprecision and inconsistency).
- (4) Indirectness: We have assured transitivity in our network by limiting the included studies to chronic fatigue syndrome with the diagnostic criteria of "1994 CDC" .We further ran various subgroup analysis, and assured that they did not violate transitivity of the network.
- (5) Publication bias: The comparison-adjusted funnel plot did not suggest obvious

publication bias. However, we cannot completely rule out the possibility that some studies are still missing. Considering that the field of CFS trials in the past has been prone to publication bias, the review team decided by default to downgrade all the included studies for potential publication bias by one level.

	Study limitations	Imprecision	Inconsistency	Indirectness	Publication bias	GRADE
AvsB	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
AvsC	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
AvsF	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
AvsH	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
BvsC	No downgrade	Downgrade Because point estimate >1.0 but lower limit<0.80	No downgrade	No downgrade	Downgrade	LOW
BvsE	No downgrade	Downgrade Because point estimate >1.0 but lower limit<0.80	No downgrade	No downgrade	Downgrade	LOW
BvsF	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
BvsG	Downgrade because >70% contribution from moderate RoB comparisons	No downgrade	No downgrade	No downgrade	Downgrade	LOW
BvsH	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
CvsG	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
DvsF	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE
EvsF	No downgrade	No downgrade	No downgrade	No downgrade	Downgrade	MODERATE

A , acupuncture with moxibustion ; B , acupuncture ; C , moxibustion ; D ,


acupuncture with THM ; E , moxibustion with THM ; F , traditional chinses herbal medicine(THM); G , western medicine; H, no control group.

5.3 FS-14 physical score of CFS patients

5.3.1 Contribution of low or moderate RoB comparisons to each network estimate

Based on the assessment of RoB for each comparison and the contribution matrix detailing contribution of each direct comparison to all network estimates, the following bar graphs show the percentage of low or moderate RoB contributions for each network estimate.

Each bar corresponds to a NMA relative treatment effect and shows how much information comes from comparisons at low risk of bias [green] or moderate risk of bias [yellow].



7	P1	P2	P3	P4	P5	P6	P7
AvsB	8.1	0.0	0.0	0.0	26.2	0.0	65.7
AvsC	0.0	77.1	5.7	11.4	0.0	5.7	0.0
AvsE	0.0	13.3	66.9	13.3	0.0	6.6	0.0
BvsC	0.0	43.5	21.8	12.9	0.0	21.8	0.0
BvsD	8.1	0.0	0.0	0.0	26.2	0.0	65.7
BvsE	0.0	1.9	0.9	1.9	0.0	95.3	0.0
CvsD	8.1	0.0	0.0	0.0	26.2	0.0	65.7
AvsD	8.1	0.0	0.0	0.0	26.2	0.0	65.7
CvsE	1.9	41.6	2.8	5.6	6.2	26.4	15.5
EvsD	8.1	0.0	0.0	0.0	26.2	0.0	65.7

Compaision	AvsB	AvsC	AvsE	BvsC	BvsD	BvsE	CvsD	AvsD	CvsE
Moderate	91.9%	94.3%	93.4%	78.2%	91.9%	4.7%	91.9%	91.9%	71.7%

percent									
EvSd	Entire network								
91.9%	79.6%								

5.3.2 Table of reasons for downgrading

Based on all the above information, we GRADEd each network estimate according to the following criteria.

- (1) Study limitations: We downgraded by one level when the contributions from low RoB comparisons were less than 30% and contributions from moderate RoB comparisons were 70% or greater.
- (2) Imprecision: We considered a clinically meaningful threshold for OR to be 0.80 or 1.25 and downgraded the estimate if the OR point estimate is 1 or more and the lower limit of its CrI is below 0.80; or if the OR point estimate is less than 1 and the upper limit of its CrI is above 1.25.

- (3) Inconsistency: We rated two concepts, heterogeneity and incoherence (inconsistency), in this domain.

For heterogeneity, we looked at the common tau and found that it is low compared to the expected value as reported in the literature (Turner RM et al (2012) Int J Epidemiol, 41, 818-827) , so we did not downgrade any network estimate for heterogeneity. For inconsistency, we looked at the results of side splitting and we downgraded the comparisons with important inconsistency ($p < 0.05$), where we have not downgraded for imprecision (we did not downgrade the same network estimate for both imprecision and inconsistency).

- (4) Indirectness: We have assured transitivity in our network by limiting the included studies to chronic fatigue syndrome with the diagnostic criteria of "1994 CDC" .We further ran various subgroup analysis, and assured that they did not violate transitivity of the network.

- (5) Publication bias: The comparison-adjusted funnel plot did not suggest obvious publication bias. However, we cannot completely rule out the possibility that some studies are still missing. Considering that the field of CFS trials in the past has been prone to publication bias, the review team decided by default to downgrade all the included studies for potential publication bias by one level.

	Study limitations	Imprecision	Inconsistency	Indirectness	Publication bias	GRADE
AvsB	Downgrade because >70% contribution from moderate RoB comparisons	No downgrade	No downgrade	No downgrade	Downgrade	LOW
AvsC	Downgrade because >70%	No downgrade	No downgrade	No downgrade	Downgrade	LOW

	contribution from moderate RoB comparisons					
AvsE	Downgrade because >70% contribution from moderate RoB comparisons	No downgrade	Downgrade because sidesplitting p=0.004	No downgrade	Downgrade	VERY LOW
BvsC	Downgrade because >70% contribution from moderate RoB comparisons	Downgrade Because point estimate >1.0 but lower limit<0.80	No downgrade	No downgrade	Downgrade	VERY LOW
BvsD	Downgrade because >70% contribution from moderate RoB comparisons	No downgrade	No downgrade	No downgrade	Downgrade	LOW
BvsE	No downgrade	No downgrade	Downgrade because sidesplitting p=0.001	No downgrade	Downgrade	LOW
CvsD	Downgrade because >70% contribution from moderate RoB comparisons	No downgrade	No downgrade	No downgrade	Downgrade	LOW


A, acupuncture with moxibustion; B, acupuncture; C, moxibustion; D, western medicine; E, no control group.

5.4 FS-14 mental score of CFS patients

5.4.1 Contribution of low or moderate RoB comparisons to each network estimate
Based on the assessment of RoB for each comparison and the contribution

matrix detailing contribution of each direct comparison to all network estimates, the following bar graphs show the percentage of low or moderate RoB contributions for each network estimate.

Each bar corresponds to a NMA relative treatment effect and shows how much information comes from comparisons at low risk of bias [green] or moderate risk of bias [yellow].



8	P1	P2	P3	P4	P5	P6	P7
AvsB	8.1	0.0	0.0	0.0	26.2	0.0	65.7
AvsC	0.0	77.1	5.7	11.4	0.0	5.7	0.0
AvsE	0.0	13.3	66.9	13.3	0.0	6.6	0.0
BvsC	0.0	43.5	21.8	12.9	0.0	21.8	0.0
BvsD	8.1	0.0	0.0	0.0	26.2	0.0	65.7
BvsE	0.0	1.9	0.9	1.9	0.0	95.3	0.0
CvsD	8.1	0.0	0.0	0.0	26.2	0.0	65.7
AvsD	8.1	0.0	0.0	0.0	26.2	0.0	65.7
CvsE	1.9	41.6	2.8	5.6	6.2	26.4	15.5
EvsD	8.1	0.0	0.0	0.0	26.2	0.0	65.7

Comparison	AvsB	AvsC	AvsE	BvsC	BvsD	BvsE	CvsD	AvsD	CvsE
Moderate percent	91.9%	94.3%	93.4%	78.2%	91.9%	4.7%	91.9%	91.9%	71.7%
EvsD	Entire network								
91.9%	79.6%								

5.4.2 Table of reasons for downgrading

Based on all the above information, we GRADEd each network estimate according to the

following criteria.

- (1) Study limitations: We downgraded by one level when the contributions from low RoB comparisons were less than 30% and contributions from moderate RoB comparisons were 70% or greater.
- (2) Imprecision: We considered a clinically meaningful threshold for OR to be 0.80 or 1.25 and downgraded the estimate if the OR point estimate is 1 or more and the lower limit of its CrI is below 0.80; or if the OR point estimate is less than 1 and the upper limit of its CrI is above 1.25.
- (3) Inconsistency: We rated two concepts, heterogeneity and incoherence (inconsistency), in this domain.
For heterogeneity, we looked at the common tau and found that it is low compared to the expected value as reported in the literature (Turner RM et al (2012) Int J Epidemiol, 41, 818-827) , so we did not downgrade any network estimate for heterogeneity. For inconsistency, we looked at the results of side splitting and we downgraded the comparisons with important inconsistency ($p < 0.05$), where we have not downgraded for imprecision (we did not downgrade the same network estimate for both imprecision and inconsistency).
- (4) Indirectness: We have assured transitivity in our network by limiting the included studies to chronic fatigue syndrome with the diagnostic criteria of "1994 CDC" .We further ran various subgroup analysis, and assured that they did not violate transitivity of the network.
- (5) Publication bias: The comparison-adjusted funnel plot did not suggest obvious publication bias. However, we cannot completely rule out the possibility that some studies are still missing. Considering that the field of CFS trials in the past has been prone to publication bias, the review team decided by default to downgrade all the included studies for potential publication bias by one level.

	Study limitations	Imprecision	Inconsistency	Indirectness	Publication bias	GRADE
AvsB	Downgrade because >70% contribution from moderate RoB comparisons	No downgrade	No downgrade	No downgrade	Downgrade	LOW
AvsC	Downgrade because >70% contribution from moderate RoB comparisons	Downgrade because point estimate <1.0 but upper limit >1.25	No downgrade	No downgrade	Downgrade	VERY LOW
AvsE	Downgrade because >70%	No downgrade	Downgrade because	No downgrade	Downgrade	VERY LOW

	contribution from moderate RoB comparisons		sidesplitting p=0.004			
BvsC	Downgrade because >70% contribution from moderate RoB comparisons	Downgrade Because point estimate >1.0 but lower limit<0.80	No downgrade	No downgrade	Downgrade	VERY LOW
BvsD	Downgrade because >70% contribution from moderate RoB comparisons	No downgrade	No downgrade	No downgrade	Downgrade	LOW
BvsE	No downgrade	No downgrade	Downgrade because sidesplitting p=0.004	No downgrade	Downgrade	LOW
CvsD	Downgrade because >70% contribution from moderate RoB comparisons	No downgrade	No downgrade	No downgrade	Downgrade	LOW

A, acupuncture with moxibustion; B, acupuncture; C, moxibustion; D, western medicine; E, no control group.

Search strategy

Pubmed

History and Search Details

Download Delete

Search	Actions	Details	Query	Results	Time
#13	...	>	Search: (((((((("Acupuncture"[Mesh]) OR "Acupuncture Points"[Mesh]) OR "Acupuncture Therapy"[Mesh]) OR "Acupuncture, Ear"[Mesh]) OR "Dry Needling"[Mesh]) OR "Moxibustion"[Mesh]) OR "Trigger Points"[Mesh]) OR "Meridians"[Mesh]) OR (((((((((((((((((((acupoint injection[Title/Abstract]) OR (acupuncture[Title/Abstract])) OR (acupuncture[Title/Abstract] AND moxibustion[Title/Abstract])) OR (acupuncture points[Title/Abstract])) OR (acupuncture therapy[Title/Abstract])) OR (auricular acupuncture[Title/Abstract])) OR (auricular plaster[Title/Abstract])) OR (body acupuncture[Title/Abstract])) OR (coiling dragon needling[Title/Abstract])) OR (dermal needle[Title/Abstract])) OR (dry needling[Title/Abstract])) OR (ear acupuncture[Title/Abstract])) OR (ear seed pressure[Title/Abstract])) OR (Electro-acupuncture[Title/Abstract])) OR (Embedding[Title/Abstract])) OR (embedding therapy[Title/Abstract])) OR (fire needle[Title/Abstract])) OR (moxibustion[Title/Abstract])) OR (panlongci[Title/Abstract])) OR (percussopuncture[Title/Abstract])) OR (point injection[Title/Abstract])) OR (pricking blood[Title/Abstract])) OR (scalp acupuncture[Title/Abstract])) OR (trigger points[Title/Abstract])) OR (meridians[Title/Abstract])) AND ("Fatigue Syndrome, Chronic"[Mesh]) OR (((chronic fatigue syndrome[Title/Abstract]) OR (chronic fatigue[Title/Abstract])) OR (fatigue syndrome[Title/Abstract])) OR (Myalgic Encephalopathy[Title/Abstract]))	85	06:07:07
#12	...	>	Search: ("Fatigue Syndrome, Chronic"[Mesh]) OR (((chronic fatigue syndrome[Title/Abstract]) OR (chronic fatigue[Title/Abstract])) OR (fatigue syndrome[Title/Abstract])) OR (Myalgic Encephalopathy[Title/Abstract]))	8,371	06:06:57
#11	...	>	Search: (((((((("Acupuncture"[Mesh]) OR "Acupuncture Points"[Mesh]) OR "Acupuncture Therapy"[Mesh]) OR "Acupuncture, Ear"[Mesh]) OR "Dry Needling"[Mesh]) OR "Moxibustion"[Mesh]) OR "Trigger Points"[Mesh]) OR "Meridians"[Mesh]) OR (((((((((((((((((((acupoint injection[Title/Abstract]) OR (acupuncture[Title/Abstract])) OR (acupuncture[Title/Abstract] AND moxibustion[Title/Abstract])) OR (acupuncture points[Title/Abstract])) OR (acupuncture therapy[Title/Abstract])) OR (auricular acupuncture[Title/Abstract])) OR (auricular plaster[Title/Abstract])) OR (body acupuncture[Title/Abstract])) OR (coiling dragon needling[Title/Abstract])) OR (dermal needle[Title/Abstract])) OR (dry needling[Title/Abstract])) OR (ear acupuncture[Title/Abstract])) OR (ear seed pressure[Title/Abstract])) OR (Electro-acupuncture[Title/Abstract])) OR (Embedding[Title/Abstract])) OR (embedding therapy[Title/Abstract])) OR (fire needle[Title/Abstract])) OR (moxibustion[Title/Abstract])) OR (panlongci[Title/Abstract])) OR (percussopuncture[Title/Abstract])) OR (point injection[Title/Abstract])) OR (pricking blood[Title/Abstract])) OR (scalp acupuncture[Title/Abstract])) OR (trigger points[Title/Abstract])) OR (meridians[Title/Abstract]))	51,497	06:06:46
#7	...	>	Search: (((chronic fatigue syndrome[Title/Abstract]) OR (chronic fatigue[Title/Abstract])) OR (fatigue syndrome[Title/Abstract])) OR (Myalgic Encephalopathy[Title/Abstract]))	7,481	05:47:53

#6	...	>	Search: "Fatigue Syndrome, Chronic"[Mesh] Sort by: Most Recent	5,504	05:47:08
#5	...	>	Search: ((((((((((((((((((((((acupoint injection[Title/Abstract]) OR (acupuncture[Title/Abstract])) OR (acupuncture[Title/Abstract] AND moxibustion[Title/Abstract])) OR (acupuncture points[Title/Abstract])) OR (acupuncture therapy[Title/Abstract])) OR (auricular acupuncture[Title/Abstract])) OR (auricular plaster[Title/Abstract])) OR (body acupuncture[Title/Abstract])) OR (coiling dragon needling[Title/Abstract])) OR (dermal needle[Title/Abstract])) OR (dry needling[Title/Abstract])) OR (ear acupuncture[Title/Abstract])) OR (ear seed pressure[Title/Abstract])) OR (Electro-acupuncture[Title/Abstract])) OR (Embedding[Title/Abstract])) OR (embedding therapy[Title/Abstract])) OR (fire needle[Title/Abstract])) OR (moxibustion[Title/Abstract])) OR (panlongci[Title/Abstract])) OR (percussopuncture[Title/Abstract])) OR (point injection[Title/Abstract])) OR (pricking blood[Title/Abstract])) OR (scalp acupuncture[Title/Abstract])) OR (trigger points[Title/Abstract])) OR (meridians[Title/Abstract])	44,442	05:45:36
#4	...	>	Search: ((((((("Acupuncture"[Mesh]) OR "Acupuncture Points"[Mesh]) OR "Acupuncture Therapy"[Mesh]) OR "Acupuncture, Ear"[Mesh]) OR "Dry Needling"[Mesh]) OR "Moxibustion"[Mesh]) OR "Trigger Points"[Mesh]) OR "Meridians"[Mesh] Sort by: Most Recent	25,866	05:41:33

Showing 1 to 7 of 7 entries

EMBASE

The screenshot displays the EMBASE search results page. At the top, there are navigation tabs: Search, Emtree, Journals, Results (selected), My tools, Register, and Login. Below the navigation, there are search filters for Mapping, Date, Sources, Fields, Quick limits, EBM, Pub. types, Languages, Gender, Age, and Animal. The main content area shows a list of search results with columns for result number, search terms, and count. The results are sorted by relevance. The first result is #14, which is the search query itself, with 202 results. Other results include terms like 'body meridian', 'trigger point', 'moxibustion', 'dry needling', 'auricular acupuncture', 'acupuncture point', and 'acupuncture'.

Result #	Search Terms	Count
#14	#12 AND #13	202
#13	#10 OR #11	12,357
#12	#8 OR #9	74,727
#11	'chronic fatigue syndrome' ab,ti OR 'chronic fatigue' ab,ti OR 'fatigue syndrome' ab,ti OR 'myalgic encephalopathy' ab,ti	9,778
#10	'chronic fatigue syndrome'/exp	9,992
#9	'acupoint injection' ab,ti OR acupuncture ab,ti OR 'acupuncture points' ab,ti OR 'acupuncture therapy' ab,ti OR 'auricular acupuncture' ab,ti OR 'auricular plaster' ab,ti OR 'body acupuncture' ab,ti OR 'coiling dragon needling' ab,ti OR 'dermal needle' ab,ti OR 'dry needling' ab,ti OR 'ear acupuncture' ab,ti OR 'ear seed pressure' ab,ti OR 'electro acupuncture' ab,ti OR 'embedding' ab,ti OR 'embedding therapy' ab,ti OR 'fire needle' ab,ti OR 'moxibustion' ab,ti OR 'panlongci' ab,ti OR 'percussopuncture' ab,ti OR 'point injection' ab,ti OR 'pricking blood' ab,ti OR 'scalp acupuncture' ab,ti OR 'trigger points' ab,ti OR 'meridians' ab,ti	56,603
#8	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7	51,422
#7	'body meridian'/exp	490
#6	'trigger point'/exp	3,104
#5	'moxibustion'/exp	332
#4	'dry needling'/exp	393
#3	'auricular acupuncture'/exp	1,946
#2	'acupuncture point'/exp	47,637
#1	'acupuncture'/exp	

202 results for search #14. Set email alert, Set RSS feed, Search details, Index miner.

Results: View | Print | Export | Email | Order | Add to Clipboard. 1 —

Select number of items: Selected: 0 (clear). Show all abstracts | Sort by: Relevance, Publication Year, Entry Date.

Cochrane Library

Advanced Search

Search Search manager Medical terms (MeSH) PICO search^{BETA}

Save this search View saved searches Search help

View fewer lines Print

+				
-	+	#1	MeSH descriptor: [Acupuncture] explode all trees	MeSH 150
-	+	#2	MeSH descriptor: [Acupuncture Points] explode all trees	MeSH 1988
-	+	#3	MeSH descriptor: [Acupuncture Therapy] explode all trees	MeSH 4713
-	+	#4	MeSH descriptor: [Acupuncture, Ear] explode all trees	MeSH 193
-	+	#5	MeSH descriptor: [Dry Needling] explode all trees	MeSH 15
-	+	#6	MeSH descriptor: [Moxibustion] explode all trees	MeSH 439
-	+	#7	MeSH descriptor: [Trigger Points] explode all trees	MeSH 131
-	+	#8	MeSH descriptor: [Meridians] explode all trees	MeSH 2028
-	+	#9	(acupoint injection) ti,ab,kw OR (acupuncture) ti,ab,kw OR (acupuncture and moxibustion) ti,ab,kw OR (acupuncture points) ti,ab,kw OR (acupuncture	S Limits 14974
-	+	#10	(auricular acupuncture) ti,ab,kw OR (auricular plaster) ti,ab,kw OR (body acupuncture) ti,ab,kw OR (coiling dragon needling) ti,ab,kw OR (dermal	S Limits 1770
-	+	#11	(dry needling) ti,ab,kw OR (ear acupuncture) ti,ab,kw OR (ear seed pressure) ti,ab,kw OR (Electro-acupuncture) ti,ab,kw OR (Embedding) ti,ab,kw	S Limits 2406
-	+	#12	(embedding therapy) ti,ab,kw OR (fire needle) ti,ab,kw OR (moxibustion) ti,ab,kw OR (panlongci) ti,ab,kw OR (percussopuncture) ti,ab,kw	S Limits 2194
-	+	#13	(point injection) ti,ab,kw OR (pricking blood) ti,ab,kw OR (scalp acupuncture) ti,ab,kw OR (trigger points) ti,ab,kw OR (meridians) ti,ab,kw	S Limits 14671
-	+	#14	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13	Limits 30467
-	+	#15	MeSH descriptor: [Fatigue Syndrome, Chronic] explode all trees	MeSH 383
-	+	#16	(chronic fatigue syndrome) ti,ab,kw OR (chronic fatigue) ti,ab,kw OR (fatigue syndrome) ti,ab,kw OR (Myalgic Encephalopathy) ti,ab,kw	S Limits 8593
-	+	#17	#15 OR #16	Limits 8593
-	+	#18	#14 AND #17	Limits 349

Clear all Highlight orphan lines

Web of Science

Web of Science InCites Journal Citation Reports Essential Science Indicators EndNote Publons Kopernio Master Journal List Sign In Help English

Web of Science Clarivate Analytics

Search Tools Searches and alerts Search History Marked List

Search History Web of Science Core Collection

NOTICE: Your organization does not receive data updates to some databases in this product. More information.

Set	Results		Edit Sets	Combine Sets	Delete Sets
# 3	315	#2 AND #1 <i>Indexes=SCI EXPANDED, SSCI, AB/DCI, CPC1-S, CPCJ-SSH, BKCI-S, BKCI-SSH, ESCI, CCR EXPANDED, IC Timespan=All years</i>	Edit	<input type="radio"/> AND <input type="radio"/> OR	Select All <input type="button" value="Delete"/>
# 2	26,457	TOPIC: (chronic fatigue syndrome) OR TOPIC: (chronic fatigue) OR TOPIC: (fatigue syndrome) OR TOPIC: (fatigue syndrome,chronic) OR TOPIC: (myalgic encephalopathy) <i>Indexes=SCI EXPANDED, SSCI, AB/DCI, CPC1-S, CPCJ-SSH, BKCI-S, BKCI-SSH, ESCI, CCR EXPANDED, IC Timespan=All years</i>	Edit	<input type="radio"/> AND <input type="radio"/> OR	Select All <input type="button" value="Delete"/>
# 1	566,460	TOPIC: (acupoint injection) OR TOPIC: (acupuncture) OR TOPIC: (acupuncture points) OR TOPIC: (acupuncture therapy) OR TOPIC: (auricular acupuncture) OR TOPIC: (auricular plaster) OR TOPIC: (body acupuncture) OR TOPIC: (coiling dragon needling) OR TOPIC: (dermal needle) OR TOPIC: (dry needling) OR TOPIC: (ear acupuncture) OR TOPIC: (ear seed pressure) OR TOPIC: (electo-acupuncture) OR TOPIC: (embedding) OR TOPIC: (embedding therapy) OR TOPIC: (fire needle) OR TOPIC: (moxibustion) OR TOPIC: (panlongci) OR TOPIC: (percussopuncture) OR TOPIC: (point injection) OR TOPIC: (pricking blood) OR TOPIC: (scalp acupuncture) OR TOPIC: (trigger points) OR TOPIC: (meridians) <i>Indexes=SCI EXPANDED, SSCI, AB/DCI, CPC1-S, CPCJ-SSH, BKCI-S, BKCI-SSH, ESCI, CCR EXPANDED, IC Timespan=All years</i>	Edit	<input type="radio"/> AND <input type="radio"/> OR	Select All <input type="button" value="Delete"/>

CNKI

知网 CNKI 中文数据库

搜索框: 主题 | 中文文献, 外文文献

搜索结果: 共找到 907 条结果 1/41

全选	删除	标题	作者	来源	日期	期数	操作
<input type="checkbox"/>	<input type="checkbox"/>	慢性疲...					20
<input type="checkbox"/>	<input type="checkbox"/>	基于素...					95
<input type="checkbox"/>	<input type="checkbox"/>	周兵补中益气针刺法治疗慢性疲劳综合征临床研究	引秋霞,刘静,李静,王世广,郑楠	现代中西医结合杂志	2020-09-01	第9期	11
<input type="checkbox"/>	<input type="checkbox"/>	针灸治疗脾胃阴虚型慢性疲劳综合征的临床观察	范海旭, 黄耀麟, 陈亚斌, 何琪, 何希俊	中医药导报	2020-09-28	第9期	77
<input type="checkbox"/>	<input type="checkbox"/>	针灸治疗慢性疲劳综合征的优势方案筛选研究	张晶晶, 梁洪, 杜元洪, 李凤, 高庆平	中国中医药杂志	2020-08-28	第8期	12
<input type="checkbox"/>	<input type="checkbox"/>	五腑俞针刺加温灸治疗慢性疲劳综合征的临床观察	何思思, 黄宇燕	云南中医中药杂志	2020-07-20	第7期	31
<input type="checkbox"/>	<input type="checkbox"/>	针刺球后穴配合周六位按摩改善慢性疲劳综合征临床观察	刘银娟, 李桂家	上海针灸杂志	2020-06-16	第6期	81
<input type="checkbox"/>	<input type="checkbox"/>	升阳益胃汤联合针灸疗法治疗慢性疲劳综合征的效果研究	杨坤, 田雷松, 王平, 倪国雷	当代医药论坛	2020-05-15	第5期	32
<input type="checkbox"/>	<input type="checkbox"/>	逍遥散加味联合针刺背俞穴对肝郁脾虚型慢性疲劳综合征患者负面情绪及免疫功能的影响	赵海书, 郑楠	中国临床药理学杂志	2020-05-10	第5期	47

Wan Fang

检索

检索历史

检索表达式: ((题名或关键词("慢性疲劳综合征")或题名或关键词("疲劳综合征")或题名或关键词("慢性疲劳")或题名或关键词("肌性脑病"))或((主题("慢性疲劳综合征")或主题("疲劳综合征")或主题("慢性疲劳")或主题("肌性脑病"))and((题名或关键词("穴位注射")或题名或关键词("针灸")或题名或关键词("针刺")或题名或关键词("艾灸")或题名或关键词("干针")或题名或关键词("火针")或题名或关键词("耳针")或题名或关键词("电针")或题名或关键词("盘龙针")或题名或关键词("埋线"))或((主题("穴位注射")或主题("针灸")或主题("针刺")或主题("艾灸")或主题("干针")或主题("火针")或主题("耳针")或主题("电针")或主题("盘龙针")或主题("埋线"))))

资源类型: 医药、卫生

排序: 相关性 | 出版时间 | 被引频次

找到 4059 条结果

1. 刮痧治疗慢性疲劳综合征100例

[期刊论文] 宋江 - 《特别健康》 2021年14期

摘要: 目的探讨刮痧治疗慢性疲劳综合征100例方法,选择2017年2月-2020年2月我院慢性疲劳综合征患者100例作为对象,对患者进行刮痧治疗,经过治疗后对患者效果进行评估,比较所有患者的治疗前后F5-14评分比较,结果:患者经治疗,治疗总有效率逐渐增高,三个疗程的治疗后有效率均达到100%($\chi^2=5.351, P<0.05$),患者在治疗后的FS-...

刮痧治疗 慢性疲劳综合征 穴位

2. 柴胡桂枝干姜汤合当归芍药散治疗慢性疲劳综合征90例临床观察

[期刊论文] 羊浩 - 《健康大视野》 2020年7期

CQVIP

检索说明

逻辑运算符: AND (逻辑“与”)、OR (逻辑“或”)、NOT (逻辑“非”);
字段标识符: U=任意字段、M=题名或关键词、K=关键词、A=作者、C=分类号、S=机构、J=刊名、F=第一作者、T=题名、R=文摘;
规则: (K=(CAD OR CAM) OR T=雷达) AND R=机械 NOT K=模具

((((((((M=针灸 OR R=针灸) OR (M=针刺 OR R=针刺)) OR (M=干针 OR R=干针)) OR (M=电针 OR R=电针)) OR (M=火针 OR R=火针)) OR (M=耳针 OR R=耳针)) OR (M=盘龙针 OR R=盘龙针)) OR (M=埋线 OR R=埋线)) OR (M=穴位注射 OR R=穴位注射)) OR (M=艾灸 OR R=艾灸)) AND (((((M=慢性疲劳综合征 OR R=慢性疲劳综合征) OR (M=疲劳综合征 OR R=疲劳综合征)) OR (M=慢性疲劳 OR R=慢性疲劳)) OR (M=肌性脑病 OR R=肌性脑病))

- 时间限定 >
- 期刊范围 >
- 学科限定 全选 >

Q检索 清空 检索历史

SionMed

AND OR NOT 更多 导出 保存策略 清除

<input type="checkbox"/>	序号	检索表达式	结果	时间	推送
<input type="checkbox"/>	3	("针刺"[常用字段:智能] OR "针灸"[常用字段:智能] OR "艾灸"[常用字段:智能] OR "穴位注射"[常用字段:智能] OR "干针"[常用字段:智能] OR "火针"[常用字段:智能] OR "电针"[常用字段:智能] OR "耳针"[常用字段:智能] OR "埋线"[常用字段:智能]) AND ("慢性疲劳综合征"[常用字段:智能] OR "疲劳综合征"[常用字段:智能] OR "慢性疲劳"[常用字段:智能] OR "肌性脑病"[常用字段:智能])	557	11:44:34	<input checked="" type="checkbox"/>
<input type="checkbox"/>	2	"针刺"[常用字段:智能] OR "针灸"[常用字段:智能] OR "艾灸"[常用字段:智能] OR "穴位注射"[常用字段:智能] OR "干针"[常用字段:智能] OR "火针"[常用字段:智能] OR "电针"[常用字段:智能] OR "耳针"[常用字段:智能] OR "埋线"[常用字段:智能]	239457	11:44:11	<input checked="" type="checkbox"/>
<input type="checkbox"/>	1	"慢性疲劳综合征"[常用字段:智能] OR "疲劳综合征"[常用字段:智能] OR "慢性疲劳"[常用字段:智能] OR "肌性脑病"[常用字段:智能]	7826	11:42:35	<input checked="" type="checkbox"/>

AND OR NOT 更多 导出 保存策略 清除